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ABSTRACT 
Discovery of Discriminative LC-MS and 1H NMR Metabolomics Markers 
Geoffrey T. Gipson 
Bahrad A. Sokhansanj, Ph.D. 
 
 
 
 
 There is a growing trend to look for novel markers of altered phenotype that are 
not associated with existing biological knowledge.  This exploratory approach has led to 
greater emphasis on generating and analyzing large amounts of data simultaneously.  
Discovery of metabolic markers through analysis of non-targeted, high-throughput data is 
a challenging, time-consuming process.  Two of the most popular analytical techniques in 
metabolic profiling are 1H Nuclear Magnetic Resonance (NMR) spectroscopy and Liquid 
Chromatography (LC) -Mass Spectrometry (MS).  There are many challenges associated 
with the interpretation of these complex metabolomic datasets and automated methods 
are critical for extracting biologically meaningful information from them.   
 This work describes the development and application of several novel approaches 
for the analysis and interpretation of NMR and LC-MS data.  A weighted, constrained 
least-squares algorithm which uses a linear mixture of reference standard data to model 
complex urine NMR spectra is discussed.  This method was evaluated through 
applications on simulated and experimental datasets.  The evaluation of this method 
suggests that the weighted least-squares approach is effective for identifying biochemical 
discriminators of varying physiological states.  Next, a method for clustering MS 
instrumental artifacts and a stochastic local search algorithm for the automated 
assignment of large, complex MS-based metabolomic datasets is presented.  Instrumental 
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clusters, peaks grouped together by shared peak shape in the temporal domain, serve as a 
guide for the number of assignments necessary to completely explain a given dataset.  
Mass only assignments are then refined through the intersection of peak correlation pairs 
with a database of biochemically relevant interaction pairs.  Further refinement is 
achieved through a stochastic local search optimization algorithm that selects individual 
assignments for each instrumental cluster.  The algorithm works by choosing the peak 
assignment that maximally explains the connectivity of a given cluster.  The findings 
indicate that this methodology provides a significant advantage over standard methods 
for the assignment of metabolites in an LC-MS dataset. 
 Finally, a multi-platform (NMR, LC-MS, microarray) investigation of metabolic 
disturbances associated with the leptin receptor defective (db/db) mouse model of type 2 
diabetes using the developed methodologies is described.  Several urinary metabolites 
were found to be associated with diabetes and/or diabetes progression and confirmed in 
both NMR and LC-MS datasets.  The confirmed metabolites were trimethylamine-n-
oxide (TMAO), creatine, carnitine, and phenylalanine.  Additionally, many metabolic 
markers were found by either NMR or LC-MS, but could not be found in both, due to 
instrumental limitations.  This indicates that the combined use of NMR and LC-MS 
instrumentation provides complementary information that would be otherwise 
unattainable.  Pathway analyses of urinary metabolites and liver, muscle, and adipose 
tissue transcripts from the db/db model were also performed.  Metabolite and liver 
transcript levels associated with the TCA cycle and steroid processes were altered in 
db/db mice, as was gene expression in muscle and liver associated with fatty acid 
processing.  The findings implicate a number of processes known to be associated with 
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diabetes and reveal tissue specific responses to the condition.  When studying metabolic 
disorders such as diabetes, platform integrated profiling of metabolite alterations in 
biofluids can provide important insight into the processes underlying the disease.   
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CHAPTER 1: Introduction 
 
1.1 Motivation 
 There is a growing trend to look for experimental effects (e.g. disease status, toxic 
response, etc.) that are not pre-selected based on a hypothesis derived from knowledge of 
the underlying disease state (Buetow et al., 2001; Chatterjee et al., 2006).  In the pursuit 
of this aim, more emphasis is placed on generating and interpreting large datasets of an 
unspecified mix of chemical classes and biological origins, attempting to capture the 
whole of the metabolome in only a few broadly-detecting analytical technologies.   
Metabolomics has been described as the “comprehensive and quantitative analysis of all 
metabolites” (Fiehn, 2001) and the comparison of many tissue- or biofluid- derived 
biochemical variables between test and control subjects (Lindon et al., 2004).  
Metabolomics data can be used in a number of ways, one of which is for the discovery of 
biomarkers.  This has the potential advantage of assisting in novel biomarker discovery 
for disease areas that are not well characterized or understood.  
 Biomarkers are compounds (transcripts, proteins, metabolites, etc.) that indicate a 
specific change in the physiological state of an organism.  Biomarkers can be used to 
indicate either the presence of a disease or the efficacy or toxicity of a drug (Lindon et 
al., 2004; Witkamp, 2005).  However, typically a marker is not immediately evaluated 
across a sufficient number of conditions to establish the specificity requirement of a 
biomarker.  As such, the term discriminative marker will be used here to describe a 
marker that is indicative of an experimental change, but not necessarily unique to this 
particular group change.  Discriminative markers are typically sought through 
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investigations utilizing high throughput methodologies such as transcriptomics, 
proteomics, and metabolomics.  Following biomarker discovery, independent 
applications with more simple detection assays can be utilized (Witkamp, 2005).  Since 
metabolomics provides direct biochemical information, and potentially biomarkers that 
can be easily tracked over time in human studies, it is likely that it will have a greater 
impact on drug discovery than transcriptomics or proteomics (Lindon et al., 2004). 
 Metabolomics is an area of increasing scientific interest and promise.  To date, the 
most widely utilized data generation technologies for mammalian metabolomics 
investigations have been either 1H nuclear magnetic resonance spectroscopy (NMR) or 
mass-spectrometry (MS) -based (Dunn and Ellis, 2005).  Due to the nature of 
spectroscopic techniques, both of these platforms are associated with output signal 
complexity and subsequent interpretation difficulties.  As such, metabolomics 
investigators and spectroscopists spend a great deal of time and effort extracting 
meaningful information from such datasets (Robertson, 2005). 
 There are significant challenges associated with signal processing with new 
methods needed to ensure that the metabolite information can be extracted from these 
complex datasets free of experimental confounding factors. Substantial informatics 
method development is also needed to extract biologically meaningful information from 
these complex datasets for statistical evaluation, interpretation of confounding factors, 
and chemical identification. 
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Figure 1.1.  NMR instrument from which data in these studies was collected. 
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Figure 1.2.  LC-MS instrument from which data in these studies was collected.
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1.2 Nuclear Magnetic Resonance Spectroscopy 
  NMR is an important “omics” platform because of its ability to readily and 
reproducibly assay accessible samples from blood, urine, other fluids, or tissue extracts 
and it is relatively inexpensive (Griffin and Bollard, 2004).  This makes it an amenable 
platform to identify and validate key discriminative markers of disease, drug efficacy, 
toxicity, or other physiological parameters (e.g. gender, age, metabolic status). 
Commonly, NMR datasets are analyzed by applying univariate and multivariate 
statistical approaches to discrete spectral regions in an attempt to identify regions that are 
altered by a perturbation (e.g. a group difference arising from genetic modification or 
xenobiotic treatment).  Following identification of regions of interest, metabolites with 
resonances associated with these regions are investigated more closely via manual visual 
inspection of spectra and additional analytical assays.  The chemical shift position and 
intensity of all NMR resonances for a particular metabolite, which could be termed its 
‘NMR signature,’ are essential for definitive metabolite identification.  Based on the 
NMR signature, a metabolite assignment can often be confirmed unambiguously by 
comparison with database information, using standard one and two dimensional NMR 
experiments.  However, this process can be very time consuming to do manually, even 
for known, well characterized entities.  Additionally, peak overlap can make this 
straightforward NMR identification impossible for some metabolites without partial or 
complete purification prior to NMR.  This is particularly the case for some sugars that 
contain no clear anomeric proton signal, overlapping fatty acid signals, and certain amino 
acids. 
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Direct (absolute or relative) quantification of compound levels via spectral 
analyses of NMR data would be of great value to metabolomics investigators, yet there 
are a number of challenges that must be overcome to achieve this task.  Biofluid NMR 
spectra are the integration of many individual overlapping metabolite spectral features 
(i.e. peaks).  In highly proteinaceous biofluids (e.g. blood plasma or serum), low 
molecular weight metabolites are often protein bound, rendering them less amenable to 
reliable quantification by NMR, because of line-broadening and loss of NMR visibility 
(Nicholson et al., 1995).  In urine, however, all metabolites above the detection limit with 
non-labile protons are observed, which leads to highly complex spectra (Figure 1.3).  
Additionally, there is a much larger variability in the physico-chemical parameters (i.e. 
pH, ionic strength, compound concentrations) of urine compared to more 
homeostatically-controlled biofluids such as serum, which can affect the absolute 
positioning of corresponding peaks across multiple samples (Lindon et al., 2000).  
Several techniques are commonly implemented to reduce the impact of peak shift (e.g. 
spectral region binning, spectral alignment) and continue to be developed and refined to 
deal with this inter-individual variation (Trbovic et al, 2005; Lefebvre).  As such, while 
the global quantitative analysis of NMR spectra derived from biofluids and tissue extracts 
is challenging, signal quantification in urine samples presents additional difficulties. 
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Figure 1.3.  Complex biofluid NMR spectra.
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1.3 Mass Spectrometry 
MS methods are useful data platforms for metabolomics investigators (Want et 
al., 2005) and can be used for either targeted or non-targeted analyses (Halket et al., 
2005).  A particular challenge of metabolite profiling, whether using MS or nuclear 
magnetic resonance (NMR), is assignment of spectral peaks of interest (Kell, 2004).  
Targeted MS analyses, in which a small number of predefined analytes of related 
chemical class are examined, are commonly used as a more accurate follow-up on 
putative metabolites proposed by a high-throughput method (e.g. NMR, non-targeted LC-
MS).  Non-targeted MS analyses are global investigations of compounds found within an 
analytical sample (Figure 1.4).   
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Figure 1.4.  LC-MS data from global metabolic profiling of urine from mice of 2 different genotypes. 
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Previously described informatics methods have been developed to help to reduce 
this major bottleneck, although most of the approaches have not yet been fully validated 
in the context of analytically confirmed assignments.  The proposed solutions have 
employed mass only database search methods (Smith et al., 2006), refined mass database 
search methods utilizing isotopic patterns (Kind and Fiehn, 2006), mass spectral libraries 
(Kopka et al., 2005), and ab initio mass transformation pairs (Breitling et al., 2006a; 
2006b) for the putative assignment of metabolites in high-throughput metabolomic 
datasets.   
Correlation networks of the assigned components of metabolomic datasets have 
been suggested for the construction of metabolic networks (Arkin et al., 1997, Steuer et 
al., 2003a).  Although metabolic neighbors in shared biochemical pathways have been 
observed to be significantly correlated, evaluations of modeled and experimental data 
suggest that observed correlation networks do not “necessarily” reflect underlying 
pathway structure and correlations often exist that are inexplicable given current 
biochemical knowledge (Steuer et al., 2003a; 2003b; Steuer, 2006).  Although not all 
metabolite correlations “necessarily” provide information useful for assignment within 
the context of existing biochemical pathways, however, those correlations which intersect 
with described biochemical interactions can likely be used to inform the assignment of 
MS data peaks.  In other words, while current understanding of biochemical interactions 
is incomplete and cannot fully characterize the pathway relationships underlying 
observed metabolite correlations, it is hypothesized that existing biochemical knowledge 
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provides useful information for the assignment of unknown compounds in large 
metabolomic datasets.   
In a recently described method for ab initio metabolic network prediction, 
investigators present a method for assignment of putative metabolite transformation pairs 
using ultra high mass accuracy MS methods coupled with mass searches focused on 
metabolic transformations (Breitling et al., 2006a).  The method identifies a series of 
putative ion reaction pairs by mapping peak mass differences to biochemical 
transformation reactions.  According to the authors, one of the benefits of this analysis is 
that their network links are directly associated with known chemical reactions, exceeding 
the level of descriptive connectivity of metabolite correlation networks.  Here, a method 
is presented that provides explicit biological meaning to observed data relationships 
which can provide insight into the assignment of features in MS-based datasets. The 
method is intended to be a useful assignment tool, even for lower mass accuracy 
instruments that are in common use.  However, improving the mass accuracy will likely 
improve obtained results. 
A recent review of MS-based metabolomics describes the current usage of 
biochemical databases as a means to infer biological function of previously identified 
metabolites (Dettmer et al., 2007).  Applications utilizing existing biochemical pathways 
include visualization (Mendes, 2002) and metabolic flux analysis (Forster et al., 2002).  
However, a global, systematic intersection of metabolite correlation pairs with a database 
of biochemical interaction pairs has not yet been described.     
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1.4 Metabolic Study of Murine Diabetes 
In both the United States and worldwide, the prevalence of diabetes is increasing.  
In 2003, there were approximately 194 million affected adults (5.1% global population), 
and by 2025, it is projected that the incidence of diabetes will reach 333 million adults 
(6.3% global population).   Type 2 diabetes accounts for approximately 90% of all 
diabetes cases and is projected to be the primary cause of the increasing incidence rate 
(International Diabetes Federation, 2005). 
Of all the animal models available for the investigation of type 2 diabetes, rodent 
models have been the most popular due to short generation time, heritable traits, and cost.  
The most studied spontaneously diabetic mouse model is the db/db mouse, which, due to 
an autosomal recessive defect in the leptin receptor gene, displays several phenotypic 
traits associated with type 2 diabetes (Chen and Wang, 2005) including drastically altered 
metabolic processes.  The widespread metabolic changes associated with diabetes make 
metabolic profiling a particularly important contribution to the discussion of disease 
progression and prevention. 
1.5 Cross-platform Metabolomic Analyses 
 The use of NMR and LC-MS methods in conjunction for metabolomics studies is 
relatively new, though some examples can be found in the literature (Lenz et al., 2004a; 
2004b; Williams et al., 2005a; Crockford et al., 2006).  Methods proposed for the co-
analysis of multiple types of spectroscopic metabolomics data include statistical 
heterospectroscopy (Crockford et al., 2006) and data fusion (Smilde et al., 2005).  Data 
fusion can and has been applied in many areas of scientific inquiry due to the generic 
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nature of the data integration.  Recently, it has been used in another field of high 
throughput biology, genomics (Lanckriet et al., 2004). 
 The integrated analysis of metabolomics data from multiple data platforms is an 
active area of research (Smilde et al. 2005; Crockford et al. 2005).  Data fusion attempts 
to integrate multiple datasets, each with a different “view”, into a comprehensive 
description of the test subject.  Such integrated analyses are not unique to metabolomics, 
and have been applied in many scientific fields, including genomics (Lanckriet et al. 
2004).  Data fusion can be implemented at many different levels of inquiry.  At some 
point, the fusion always consists of combining features from the various platforms into an 
individual feature vector.  The data integration can be performed: early in the analysis 
process, meaning that all measured variables from an individual are fused prior to any 
data processing; late in the process, following high level feature selection on the 
individual platforms; or anytime in between.  In the study of the leptin defective murine 
model of diabetes described here, comparisons are made at the level of data features with 
confirmed metabolite assignments. 
1.6 Approach 
1.6.1 Nuclear Magnetic Resonance Spectroscopy 
A number of attempts have been made to decompose NMR spectra into individual 
components (e.g. independent component analysis, molecular factor analysis) without 
any prior knowledge of the underlying data structure (Ladroue et al., 2003; Eads et al., 
2004; Scholz et al., 2004; Stoyanova et al., 2004a).  The primary disadvantage of these 
methods continues to be the difficulty in interpreting the results within a biochemical 
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context.  In other words, since there is no underlying metabolite data structure built into 
these methods, the components rarely match known metabolite profiles. 
Several fitting methods utilizing combinations of empirically derived or modeled 
reference spectra exist (Provencher, 1993; Crockford et al., 2005; Chenomx, Inc.).  A 
previous study examining a longitudinal NMR dataset suggested the use of weighted 
principal components analysis (PCA) to provide an alternative view of the data versus 
unweighted PCA (Jansen et al., 2004).  However, differentially weighting spectral 
regions in the process of deconvolving NMR spectra into individual metabolite levels has 
not previously been described. 
Here, a weighted, constrained least-squares algorithm is used for the estimation 
and comparison of relative metabolite levels (referenced to control values of the same 
metabolite) across groups of divergent physiological states.  The aim of this work is to 
demonstrate that deconvolving complex spectra with the incorporation of a non-uniform 
weighting scheme, will lead to the identification of metabolites of biological interest that 
would be missed otherwise.  In order to efficiently deconvolve the spectra into individual 
component spectra, it is often necessary to account for heterogeneous interference.  In 
other words, the signal of certain metabolites of interest may be deeply buried in certain 
spectral regions, but easily distinguished in others.  Additionally, incorporating statistical 
information about the signal of interest into the deconvolution algorithm can be useful.  
Previous methods of linear deconvolution (i.e. LCModel) place equal weight on all 
spectral regions when fitting additive models (Provencher, 1993; 2001).  The novelty of 
this approach for deconvolving complex NMR spectra lies in the application of a 
weighted, constrained least-squares method for identifying metabolites that may be 
15 
 
 
discriminative markers of biological effect based on the relative quantitative estimate in 
context of scaled, control intensities. 
1.6.2 Mass Spectrometry 
Here, a method is presented that selects likely metabolite candidates and increases 
confidence in metabolite assignment.  Specifically, the method will identify metabolites 
in an ultra performance liquid chromatography (UPLC)-MS dataset by mapping peak 
interaction pairs (significantly correlated peak pairs) onto interaction pairs from the 
Kyoto Encyclopedia of Genes and Genomes (KEGG) (Kanehisa et al., 2006) using mass 
matching.  Anticipated benefits of this methodology include robustness to varying 
instrumental mass accuracy and immediate placement of annotated metabolites into an 
explicit biological context. 
An additional challenge of MS-based metabolomics assignment is the 
differentiation between mass differences associated with in vivo transformation and those 
which are artifacts of MS instrumentation.  To address this, artifactual peaks (e.g. 
fragments, oligomers) should be identified to avoid assigning biological meaning to 
highly correlated peak pairs which are measurements of the same metabolite.  To avoid 
annotation of instrumental artifacts, peaks appearing to share the same compound source 
are grouped into “instrumental clusters.”  This has previously been performed manually 
through visual inspection of data peaks.  In this study, instrumental clustering was 
automated and integrated into the assignment algorithm.    
A previous study (Breitling et al., 2006a) attempted to minimize the assignment of 
instrumental artifacts using a refined, a priori set of biochemically meaningful mass 
differences.  Here, peaks with shared temporal peak shapes are clustered in order to 
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distinguish between instrumental and biological peak relationships.  To this end, and to 
aid the development of the automated assignment tool, both (i) an artificial biofluid 
matrix consisting of metabolite standards, and (ii) urine from diabetic and healthy mice 
were evaluated.  These findings were validated by analytical confirmation of the 
metabolite identity. 
1.6.3 Cross-platform Metabolic Study of Murine Diabetes 
1H nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry- 
(MS) based technologies are the most commonly used for mammalian metabolomics 
(Dunn and Ellis, 2005).  Both approaches allow for the simultaneous measurement of a 
large number of individual metabolites, allowing investigators to identify and validate 
key discriminative markers of disease, drug efficacy, toxicity, or other physiological 
parameters.  Consistency and reproducibility are considered a distinct advantage for the 
use of NMR in metabolic profiling studies (Keun et al., 2002).  MS-based methods are 
also important data platforms and have the specific advantage of a lower detection limit 
(Want et al., 2005).  However, MS data are not as reproducible as NMR due to a non-
linear detector response and ionization.  A recent review of metabolic profiling 
techniques (Wilson et al., 2005) discussed several comparison studies of MS-based and 
NMR metabolomics and highlighted the “complementary nature” of the two 
technologies, concluding that both techniques should be used in conjunction whenever 
reasonable. 
The goal of this study was to provide biological insight into metabolic alterations 
associated with diabetes and diabetic progression.  A number of metabolic profiling 
studies of diabetes have been conducted evaluating rodent models (Williams et al., 2006), 
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humans (van Doorn et al., 2006), and cross-species comparisons (Salek et al., 2007).  In 
contrast to these studies, an evaluation of cross -experimental and -platform results for 
consistency within the context of the biological analysis were performed in this study.  
To accomplish this, standard and novel methodologies (Gipson et al., 2006; 2008) were 
applied to extract information of biological importance from NMR and LC-MS profiles 
of urine from db/db and control (db/+) mice.  These metabolite data, collected over two 
independent experiments, are put into context with a gene expression dataset that was 
collected during one of the experimental periods.  Additionally, technical issues 
concerning the use of NMR and LC-MS data in metabolomics investigations are 
discussed. 
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CHAPTER 2: Weighted least-squares deconvolution method for discovery of group 
differences between complex biofluid 1H NMR spectra 
 
2.1 Summary 
This chapter discusses a novel approach for estimating metabolite levels from 1H NMR 
metabolomics data and has been modified from an article published in the Journal of 
Magnetic Resonance (Gipson et al., 2006) with permission from Elsevier.  This work was 
done in collaboration with Dr. Kay Tatsuoka, Dr. Brian Sweatman, and Dr. Susan 
Connor.  The majority of the introductory material from this chapter is also located in 
Chapter 1, but has been reproduced here to provide the information in the original 
context.  Biomarker discovery through analysis of high-throughput NMR data is a 
challenging, time-consuming process due to the requirement of sophisticated, dataset 
specific pre-processing techniques and the inherent complexity of the data.  Here, the use 
of weighted, constrained least-squares for fitting a linear mixture of reference standard 
data to complex urine NMR spectra as an automated way of utilizing current assignment 
knowledge and the ability to deconvolve confounded spectral regions is described.  
Following the least-squares fit, univariate statistics were used to identify metabolites 
associated with group differences.  This method was evaluated through applications on 
simulated datasets and a murine diabetes dataset.  Furthermore, the differential ability of 
various weighting metrics to correctly identify discriminative markers is explored.  The 
study findings suggest that the weighted least-squares approach is effective for 
identifying biochemical discriminators of varying physiological states.  Additionally, the 
superiority of specific weighting metrics is demonstrated in particular datasets.  An 
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additional strength of this methodology is the ability for individual investigators to couple 
this analysis with laboratory specific pre-processing techniques. 
2.2 Introduction  
Metabolomics is an area of increasing scientific interest and promise.  To date, the 
most widely utilized data generation technologies for mammalian metabolomics 
investigations have been either 1H NMR- (NMR) or MS-based (Dunn and Ellis, 2005).  
NMR is an important “omics” platform because of its ability to readily and reproducibly 
assay accessible samples from blood, urine, other fluids, or tissue extracts.  This makes it 
an amenable platform to identify and validate key discriminative markers of disease, drug 
efficacy, toxicity, or other physiological parameters (e.g. gender, age, metabolic status). 
Commonly, NMR datasets are analyzed by applying univariate and multivariate 
statistical approaches to discrete spectral regions in an attempt to identify regions that are 
altered by a perturbation (e.g. a group difference arising from genetic modification or 
xenobiotic treatment).  Following identification of regions of interest, metabolites with 
resonances associated with these regions are investigated more closely via manual visual 
inspection of spectra and additional analytical assays.  The chemical shift position and 
intensity of all NMR resonances for a particular metabolite, which could be termed its 
‘NMR signature,’ are essential for definitive metabolite identification.  Based on the 
NMR signature, a metabolite assignment can often be confirmed unambiguously by 
comparison with database information, using standard one and two dimensional NMR 
experiments.  However, this process can be very time consuming to do manually, even 
for known, well characterized entities.  Additionally, peak overlap can make this 
straightforward NMR identification impossible for some metabolites without partial or 
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complete purification prior to NMR analysis.  This is particularly the case for some 
sugars that contain no clear anomeric proton signal, overlapping fatty acid signals, and 
amino acids. 
Direct (absolute or relative) quantification of compound levels via spectral 
analysis of NMR data would be of great value to metabolomics investigators, yet there 
are a number of challenges that must be overcome to achieve this task.  Biofluid NMR 
spectra are the integration of many individual overlapping metabolite spectral features 
(i.e. peaks).  In highly proteinaceous biofluids (e.g. blood plasma or serum), low 
molecular weight metabolites are often protein bound, rendering them less amenable to 
reliable quantification by NMR, because of line-broadening and loss of NMR visibility 
(Nicholson et al., 1995).  In urine, however, all metabolites above the detection limit with 
non-labile protons are observed, which leads to highly complex spectra.  Additionally, 
there is a much larger variability in the physico-chemical parameters (i.e. pH, ionic 
strength, compound concentrations) of urine compared to more homeostatically-
controlled biofluids such as serum, which can affect the absolute positioning of 
corresponding peaks across multiple samples (Lindon et al., 2000).  Several techniques 
are commonly implemented to reduce the impact of peak shift (e.g. spectral region 
binning, spectral alignment) and continue to be developed and refined to deal with this 
inter-individual variation (Trbovic et al, 2005; Lefebvre).  As such, while the global 
quantitative analysis of NMR spectra derived from biofluids and tissue extracts is 
challenging, signal quantification in urine samples presents additional difficulties. 
A number of attempts have been made to decompose NMR spectra into individual 
components (e.g. independent component analysis, molecular factor analysis) without 
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any prior knowledge of the underlying data structure (Ladroue et al., 2003; Eads et al., 
2004; Scholz et al., 2004; Stoyanova et al., 2004a).  The primary disadvantage of these 
methods continues to be the difficulty in interpreting the results within a biochemical 
context.  In other words, since there is no underlying metabolite data structure built into 
these methods, the components rarely match known metabolite profiles. 
Several fitting methods utilizing combinations of empirically derived or modeled 
reference spectra exist (Provencher, 1993; Crockford et al., 2005; Chenomx, Inc.).  A 
previous study examining a longitudinal NMR dataset suggested the use of weighted 
principal components analysis (PCA) to provide an alternative view of the data versus 
unweighted PCA (Jansen et al., 2004).  However, differentially weighting spectral 
regions in the process of deconvolving NMR spectra into individual metabolite levels has 
not previously been described. 
Here, the use of a weighted, constrained least-squares algorithm for the estimation 
and comparison of relative metabolite levels (referenced to control values of the same 
metabolite) across groups of divergent physiological states is proposed.  The aim is to 
demonstrate that deconvolving complex spectra with the incorporation of a non-uniform 
weighting scheme, will lead to the identification of metabolites of biological interest that 
would be missed otherwise.  In order to efficiently deconvolve the spectra into individual 
component spectra, it is often necessary to account for heterogeneous interference.  In 
other words, the signal of certain metabolites of interest may be deeply buried in certain 
spectral regions, but easily distinguished in others.  Additionally, incorporating statistical 
information about the signal of interest into the deconvolution algorithm can be useful.  
Previous methods of linear deconvolution (i.e. LCModel) place equal weight on all 
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spectral regions when fitting additive models (Provencher, 1993; 2001).  The novelty of 
the approach discussed here for deconvolving complex NMR spectra lies in the 
application of a weighted, constrained least-squares method for identifying metabolites 
that may be discriminative markers of biological effect based on the relative quantitative 
estimate in context of scaled, control intensities. 
2.3 Experimental 
2.3.1 Spectral Decomposition and Metabolite Detection 
The digitization of NMR spectral data is the fine-scale discretization of a 
continuous phenomenon.  Often, investigators find it useful to analyze NMR data at a 
coarser resolution due to inter-individual peak alignment issues.  The process of 
integrating a spectral region into larger discrete representations is commonly referred to 
as bucketing or binning.  Here, all discrete spectral representations will be referred to as 
“bins.”  However, it should be noted that the algorithm described here can be applied to 
discrete spectral data of any resolution, including raw digitized spectra.   
An NMR spectrum is the summation of the intensities of multiple, individual 
metabolite spectra.  Though it is unreasonable to assume that an investigator will have a 
complete (i.e. all compounds present in a given biofluid) set of reference standards, all 
available, characterized metabolites should be incorporated into the analysis.  Eq. [2.1] 
expresses the relationship between the observed intensity at bin l of subject j (djl), the 
unknown intensity of metabolite k of subject j (mjk), and the relative intensity of known 
metabolite k in bin l (ikl).      
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                                                                                   (Eq. 2.1) 
                                                           
Since many metabolites are simultaneously detected during a single NMR data 
acquisition, and the intensity level of individual bins may be a result of contributions 
from several metabolites, the identification and quantification of individual metabolites 
measured via NMR is a challenging task.  In order to attribute the NMR spectra to 
individual metabolites, a linear model (Eq. [2.2]) was used to describe the system and 
allow for the decomposition of the NMR signal into a series of metabolite signals.  An 
important inherent property of NMR that makes this a reasonable approach is the linear 
relationship between concentration and signal intensity and hence the additivity of 
spectral intensities.   
 
                                                                D = MI                                            (Eq. 2.2) 
 
Eq. [2] represents the linear relationship between the matrix of intensity vectors 
across all individuals (D), the matrix of metabolite intensities across all individuals (M), 
and the matrix of bin-specific relative intensities across all metabolites (I).  Since actual 
metabolite levels can only have non-negative values, it makes sense to solve this linear 
system subject to the constraint that all elements in matrix M are greater than or equal to 
zero.  In order to solve the linear system subject to the inequality constraints, the 
Penalized Constrained Least Squares Fitting (pcls) function within the mgcv library 
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(version 1.3-1) of R (Wood, 1994; 2000; 2004; R Development Core Team) is used.  The 
pcls algorithm finds the minimum sum of squares, subject to the non-negativity criteria 
(Eq. [2.3]) through quadratic programming.  Although this function has the capability of 
fitting non-linear, penalized regression splines, it is used here to calculate the weighted, 
constrained linear fit.  As such, the use of penalties is unnecessary.  The pcls function is 
executed iteratively to estimate the M matrix piecewise (Mcalc) by minimizing a function 
of the weighting vector (w), individual metabolite vectors (mj), and individual data 
vectors (dj), for each individual in the dataset. 
  
                                       min || w  (mjI –dj) ||2  subject to mjI > 0
v
                (Eq. 2.3) 
 
The pcls method requires that the I matrix be of full column rank.  Prior to 
implementing the pcls function, the rank of the I matrix is verified via QR decomposition, 
and all rank deficiencies are eliminated.  Since the I matrix is strictly non-negative, the 
estimated metabolite intensity levels are constrained from taking negative values.  Mcalc 
contains information regarding the relative quantities of the characterized metabolites 
across the individuals in the dataset.   
In addition to providing inter-metabolite relative quantities for an individual, Mcalc 
can also provide insight into metabolite production between individuals or groups of 
individuals.   For example, the fold change of an individual metabolite k between two 
groups or the correlation between two metabolites can be calculated using the estimated 
metabolite levels. 
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2.3.2 Constrained Least-Squares estimates   
Although there are an enormous number of possible weighting vectors to utilize in 
the least-squares analysis, the focus here is placed on two non-uniform vectors and a 
uniform weighting vector.  In order to demonstrate the utility of “clear” spectral regions, 
an examination of a relatively low intensity metabolite, found in areas of both high and 
low interference and altered between two groups, will be instructive.  Incorporation of 
information regarding the relative interference of the different spectral regions was 
achieved through using the inverse of the number of observed metabolites in a given 
spectral region as the weighting vector.  Constrained least-squares (CLS) will be used to 
estimate the underlying metabolite intensity levels both with the inverse metabolite count 
weighting vector (mCLS) and with a uniform, or non-weighted, vector (nwCLS).   
Additionally, a weighting vector was used that incorporated the binwise group 
variance to extract the underlying metabolites of interest (vCLS).  More specifically, the 
weight of each bin was calculated as the inverse of the square-root of the product of the 
variances (1/ 21σσ ) of the bin intensities of the 2 groups of interest.  The mCLS and 
vCLS weighting factors were implemented with the specific aim of algorithmically 
placing more emphasis on fitting bins that were less confounded and more consistent 
across biological replicates, respectively.   
2.3.3 Simulations 
The generated datasets were simulated in such a way as to closely approximate 
real NMR spectra, integrated to create sequential bins of width 0.02 ppm.  A typical 
range of NMR data spans about 10 ppm, which reduces to 500 bins, 60% of which are 
assumed to contain metabolite peaks.  Additionally, though there are thousands of 
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metabolites that could potentially be measured in biofluids, it is likely that much fewer 
make up the vast majority of the NMR signal.  Here, the data is simulated so that the 
majority of the signal is produced by no more than 300 metabolites and any other 
metabolites are at or below the limits of NMR detection.  While it is likely that these 
assumptions fairly represent a real dataset, the actual number of metabolites making up 
an NMR signal will be dependent on the sensitivity of the instrumentation being used 
(e.g. cryo versus non-cryo probe, field strength). 
All simulations consisted of 300 metabolites (150 of which were randomly 
assigned as known, i.e. contained information in the intensity matrix), 300 spectral bins, 
and 10 subjects (5 from each group).  An intensity matrix (I matrix) was randomly 
generated for all 300 metabolites (300 metabolites x 300 bins) with relative intensity 
values (U[0,1]) for an average of approximately 5 bins per metabolite (drawn from the 
empirical distribution of the reference standard assignment database) and distributed 
amongst the bins with probability according to a function of the geometric distribution 
(G[p = 0.2] +1), yielding an average of approximately 5 metabolites per bin.  The data 
matrix (D) was then calculated as the matrix product of the simulated underlying 
metabolite intensity level matrix (Minit) and the relative intensity matrix (I), followed by 
the addition of a baseline (shared across individuals) and simulated instrumental 
variability (specific to individuals), with intensity values ranging from 0% to 40% and 
0% to 10% of the mean metabolite intensity level, respectively.  Biological variation was 
simulated via sampling individual metabolite levels from a normal distribution when 
generating Minit.  Once the D matrix was generated (10 individuals x 300 bins), 150 of the 
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metabolites were randomly withheld from the I matrix in order to simulate the reality of 
incomplete metabolite information in metabolomics studies.     
2.3.4 Spectral regions with a single metabolite resonance (clear spectral regions) 
Non-weighted linear deconvolution methods may miss biologically important 
compounds when there is a high level of interference in spectral regions and the 
compound of interest is present in relatively low quantities.  To demonstrate this point, an 
NMR metabolomics dataset was simulated in which the concentrations of an individual 
metabolite, with peaks in areas of both high and low interference, were significantly 
different between two groups of subjects (10 individuals per group).  Minit (20 individuals 
x 300 metabolites) for this investigation contains 1 metabolite that is altered in one of the 
two groups and 299 that have no group difference.  The unaltered metabolite intensity 
levels were sampled from normal distributions with means ranging from 1 to 10 
(U[1,10]) and standard deviations equal to half the mean intensity value.  Altered group 
intensity levels were sampled from normal distributions with means deviating by a 
random factor (U[1.2,5]) from their baseline counterparts and the same standard 
deviations.  The direction of change of altered group intensity levels could be either 
positive or negative.  Since this method of metabolite level simulation does not strictly 
preclude the generation of negative values, and negative metabolite levels have no 
biological meaning in this context, all generated negative values were replaced by zeros. 
The I matrix was generated as described previously, with the exception that the 
number of randomly populated bins was restricted to 299.  Following the random 
generation of the 299 bin I matrix, an additional bin was added in which only the 
significant metabolite was present.  
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Univariate statistics (α = 0.05) were performed on the metabolite intensity levels 
estimated via nwCLS, mCLS and vCLS, and Minit values for the significantly altered 
metabolite.  Following classification of metabolites as having group differences or not, a 
receiver operating characteristics (ROC) analysis was performed to compare the 
sensitivity-specificity profiles of the various weighting methods.  The area under the 
curve (AUC) of the ROC curves was calculated via Somers’ rank correlation.    Pairwise 
comparisons (Bonferroni adjusted, paired t-test) were made on 200 simulations to 
determine if the various methods differed in their ability to successfully identify the 
simulated metabolite level difference.   
2.3.5 General simulation 
In order to evaluate the relative sensitivity/specificity, and to identify any 
discriminating features of the metabolites identified by different weighting factors, a 
number of simulations were performed and concurrently analyzed with and without 
weighting factors.  In this investigation 5% (15 of 300) of the initial metabolites in Minit 
(20 individuals x 300 metabolites) were generated to have group specific differences in 
intensity level. 
The metabolites intensity levels were generated in the same way as in the clear 
spectral region analysis.  Since 50% of the metabolite profiles were removed from the I 
matrix prior to analysis, on average 7-8 metabolites with simulated alterations were 
available for discovery.  Through the use of the CLS methods coupled with univariate 
statistics, true and false positives were identified.  These simulations were replicated 200 
times and the sensitivity and specificity of the CLS methods were then compared both to 
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each other as well as univariate statistics on Minit, which represents the maximum 
possible information content.   
2.3.6 Diabetes Dataset 
A large dataset of Carr-Purcell-Meiboom-Gill (CPMG) NMR spectra from urine 
samples across diabetic (db/db) and non-diabetic (db/+) mice was analyzed via CLS 
methods.  Male diabetic and control mice (8 weeks of age) were obtained from The 
Jackson Laboratory (Bar Harbor, ME).  Urine samples of 0.5% methylcellulose treated 
animals were collected over ice twice, one week apart, from mice individually housed in 
metabolism cages.  In urine samples, where there may be a wide range of ‘normal’ 
sample ionic strengths and pHs, it may be expected that differences in shift and shape 
may also occur for resonances experiencing second order coupling (e.g. lysine, 
ornithine).  This issue was addressed through the use of buffered samples, including an 
excess of phosphate buffer.  NMR spectral processing consisted of automated adjustment 
of the chemical shift of TSP to δH= 0 ppm, application of a semi-automated phase 
correction, automated baseline adjustment using an automated 0-2nd order polynomial 
and reduction to histogram representations by binning using the method by Forshed et al. 
(2002).  A bin width of 0.02 ppm was chosen with a 50% tolerance either side of the bin 
boundary.  Data were scaled using median-difference scaling of the binned data.  Further 
details concerning the experimental protocol and discriminative marker validation can be 
found in Connor et al. (in preparation). 
The nwCLS and vCLS methods were each used to deconvolve the NMR spectra 
into constituent compound intensity levels and followed by univariate statistical analyses.  
Putative discriminative markers for disease were identified through a series of Student’s 
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t-tests (α = 0.05) comparing diseased and control mice.  Specifically, a metabolite was 
considered a putative discriminative marker if an estimated metabolite level was 
significant in at least 1 of the 2 days of data.  Putative discriminative markers were 
proposed based on uncorrected and Bonferroni corrected p-values in order to verify that 
differences between the CLS methods ability to accurately identify discriminative 
markers were robust to varying thresholds of discriminative marker inclusion.  The 
results of the CLS method analyses were then compared to results from a previous study 
in which univariate and multivariate binwise analyses were utilized to identify spectral 
regions of interest, with subsequent metabolite assignment and independent validation via 
partial fractionation, LC-MS, 2D NMR, and addition of standard to confirm peak 
identity.  Direct comparisons were made between the validated discriminative marker 
assignments from the traditional analysis and the putative discriminative markers 
suggested via CLS methods.   
2.4 Results 
2.4.1 Spectral regions with a single metabolite resonance (clear spectral regions) 
In order to evaluate the different linear deconvolution methods, 200 simulations 
were performed in which one metabolite was altered and clear regions were strictly 
provided for the significantly altered metabolites.  The average ROC AUC for nwCLS, 
mCLS, vCLS, and univariate analysis of Minit were 0.92, 0.95, 0.97, and 0.97, 
respectively (Figure 2.1).  Note that univariate analysis of Minit yielded an AUC that was 
less than 1.0 due to the simulated biological variability.  Pairwise paired t-tests 
(Bonferroni corrected) were performed on the AUC estimates of each of the CLS 
methods and univariate statistics on Minit.  The results of these analyses indicate that all 
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pairwise differences except for vCLS vs. Minit were significant (nwCLS vs. mCLS, 
p<0.05; all other pairs, p<0.005).  The non-significant difference between the vCLS 
method and univariate statistics on the true underlying metabolite levels indicates that the 
variance weighting factor has achieved maximal performance in this scenario. 
 
 
 
Figure 2.1.  ROC curves comparing the performance of the nwCLS, mCLS, and vCLS methods and 
univariate analysis on Minit when at least one bin associated with the altered metabolite is uniquely 
occupied.
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2.4.2 General simulation 
In order to further evaluate the capacities of the linear deconvolution methods, 
200 simulations were performed in which 5% of the total number of metabolites were 
altered and clear regions were not strictly provided for the significantly altered 
metabolites.  The average AUC for nwCLS, mCLS, vCLS, and univariate analysis of 
Minit were 0.74, 0.75, 0.80, and 0.97, respectively.  Pairwise paired t-tests (Bonferroni 
corrected) were performed on the AUC estimates of each of the CLS methods and 
univariate statistics on Minit.  The results of these analyses indicate that all pairwise 
differences were highly significant (p<0.005), with the exception of nwCLS versus 
mCLS.  These results indicate that each of the CLS methods performed well in accurately 
discovering group differences, however, the variance weighting factor performed best.   
It is not surprising that the significant difference observed in the clear spectral 
region analysis between nwCLS and mCLS was not also observed in the general 
simulation analysis.  The mCLS method is highly dependent on the quality of the 
reference spectra (i.e. I matrix).  Real spectral libraries produced by laboratories are 
likely to have prior experience implicitly incorporated through the inclusion of 
“expected” metabolites.  In the general simulation, the random nature of the metabolite 
spectral properties (peak location, intensity, coincidence with other metabolites) and the 
random population of the I matrix leads to a situation in which any concept of prior 
experience is not modeled.  The advantage of the mCLS method in the clear spectral 
region simulation was that significantly altered metabolites were exclusively associated 
with a minimum of 1 clear bin (maximum weight), thereby providing the least-squares fit 
with a priori information concerning the quality of clear bins.  In other words, the prior 
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probability distribution that significant metabolites are associated with clear bins is not 
uninformed.  However, the prior distribution of the general simulation is uninformed, and 
therefore the specific advantage of the mCLS method is lost.  Through evaluating the 
variance of the bins, the vCLS method captures information concerning the clarity of the 
individual bins, yet is independent of specific prior knowledge.  Although the two 
weights are similar in that spectral regions with fewer observed metabolites have lower 
variance, vCLS has the added value of giving additional weight to regions with fewer 
observed and unobserved metabolites.  For this reason, and the superior performance of 
vCLS compared to mCLS in both simulation analyses, the vCLS method was chosen for 
the analysis of the diabetes dataset. 
2.4.3 Diabetes Dataset 
An investigation of the ability of the nwCLS and vCLS methods to identify the 46 
previously identified and independently validated (LC-MS, 2D-NMR, etc.) 
discriminative markers [Connor et al. (in preparation)] further demonstrates the utility of 
using weighting factors when deconvolving metabolomics datasets.  Analysis of the 
diabetes dataset with nwCLS and vCLS followed by univariate statistics (α = 0.05, p-
values unadjusted) recovered 38 and 40 of the 46 metabolites, respectively (Table 2.1).  
Adjusting the p-values for multiple comparisons led to the discovery of 35 and 38 of the 
46 metabolites via nwCLS, mCLS, and vCLS, respectively.  
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Table 2.1.  Confirmed Discriminative Markers of Diabetes and Prediction via CLS Methods 
 
nwCLS vCLS 
Metabolite 
Sig. Days pa Sig. Days pa 
2-Oxoglutarate 0 0.262 2 <0.001 
2-Hydroxyisobutyrate 2 <0.001 2 <0.001 
2-Oxoadipate 1 0.017 1 0.008 
3-Ureidopropanoate 0 0.052 2 <0.001 
Alanine 2 <0.001 2 <0.001 
Allantoin 2 0.001 0 0.085 
Citrate 1 0.002 1 0.009 
Citrulline 0 0.423 2 0.001 
Creatine 2 <0.001 1 0.039 
Creatinine 2 <0.001 0 0.090 
Formate 2 0.001 2 0.001 
Fumarate 2 <0.001 2 <0.001 
Glucose 2 <0.001 1 0.007 
Glutarate 2 <0.001 2 0.001 
Glycine 2 <0.001 2 <0.001 
Glycolate 2 <0.001 2 <0.001 
Guanidinoacetate 2 <0.001 2 <0.001 
Hippurate 1 0.003 2 <0.001 
Indoxyl sulphate 1 <0.001 2 <0.001 
Isobutyrate 2 <0.001 2 <0.001 
Isocaproate 2 <0.001 1 <0.001 
Isovalerate 0 0.077 0 1.0 
Lactate 0 1.0 0 1.0 
a value reported is the minimum unadjusted p-value 
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Table 2.1. (continued) Confirmed Discriminative Markers of Diabetes and Prediction via CLS 
Methods 
 
Lysine 2 <0.001 2 <0.001 
Malate 0 1.0 2 <0.001 
Malonate 1 0.011 2 <0.001 
Methionine 2 <0.001 1 0.001 
Methylamine 1 0.002 1 0.002 
N1-Methyl-2-pyridone-5-carboxamide 0 0.22 2 <0.001 
N1-Methyl-4-pyridone-3-carboxamide 2 <0.001 0 1.0 
N1-Methylnicotinamide 2 <0.001 2 <0.001 
N1-Methylnicotinic acid 1 0.010 2 <0.001 
N-Caproylglycine 2 <0.001 2 <0.001 
N-Butyrylglycine 2 <0.001 2 <0.001 
N-Isobutyrylglycine 2 0.001 0 0.293 
N-Isovalerylglycine 1 0.040 2 <0.001 
N-Valerylglycine 2 <0.001 2 0.001 
Nicotinamide N-oxide 2 <0.001 2 <0.001 
Orotate 1 <0.001 1 <0.001 
Pantothenate 2 <0.001 1 0.010 
Phenylacetylglycine 0 0.112 2 <0.001 
Sucrose 2 <0.001 2 <0.001 
Taurine 2 <0.001 2 <0.001 
Threonine 2 0.001 2 <0.001 
Trimethylamine 1 <0.001 2 0.006 
Valine 2 <0.001 2 <0.001 
a value reported is the minimum unadjusted p-value 
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In addition to the 46 previously confirmed discriminative markers, all methods 
predicted “significant” metabolites from the reference standard database (137 
metabolites) that have not been validated (Table 2.2).  Additional putative metabolites 
beyond the validated 46 may be confirmed as discriminative markers in the future, but 
were not followed up during the original confirmation process.  Since it is not appropriate 
to designate these putative discriminative markers as false positives, it is not possible to 
conduct a formal sensitivity/specificity analysis.  Instead, an investigation of the 
performance of randomly selecting a number of “significant” metabolites, equal to the 
number of putative discriminative markers proposed by each method, from the reference 
standard database was conducted.  After calculating how many of the putative markers 
intersect with the confirmed list of 46, it was then possible to calculate the probability 
that the performance observed by the CLS methods could be matched or surpassed 
through such a random process (Table 2.2).  This analysis (α = 0.05) revealed that 
nwCLS was not significantly different from random selection, but vCLS was 
significantly different.  This evidence further supports the idea that using weighting 
factors can increase the quality of information gained through least-squares analysis of 
NMR spectra.  
 
Table 2.2.  Discriminative Marker Prediction Performance 
 
Non-adjusted threshold Adjusted threshold 
Method 
Confirmed/Predicted p Confirmed/Predicted p 
nwCLS 38/105 0.168 26/73 0.360 
vCLS 40/106 0.042* 27/59 0.007* 
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Figure 2.2 depicts the binned spectral intensities, fitted intensities (vCLS), and the 
residual intensities for a representative control (db/+) subject.  A calculation of the 
positive (under-explained) and negative (over-explained) residuals reveals that for this 
individual, 19% of the spectrum remains unexplained and the over-explained area is 7% 
of the original spectrum.  This same individual, and a representative diabetic (db/db) 
subject, were evaluated at a higher level of detail to illustrate the capacity of the CLS 
methods to identify altered metabolites in crowded spectral regions (Figure 2.3).  Note 
that both the spectral regions and the underlying metabolite levels are decreased in the 
db/db spectra.  These changes are reflected in the accurate identification of significant 
decreases in N-caproylglycine, N-butyrylglycine, and N-valerylglycine via both the 
nwCLS and vCLS methods.   
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Figure 2.2.  Binned spectra (blue), fitted vCLS intensities (red), and residual intensities (black) for a 
representative control (db/+) subject from the first time point. 
 
 
 
 
 
Figure 2.3.  Diabetic (top) and control (bottom) spectral manually fit with reference spectra.  Relative 
intensity values (y-axis) have been scaled to allow for comparisons between the two individuals.
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2.5 Discussion 
The results from the simulation analyses demonstrate the utility of incorporating 
specific domain knowledge into the biomarker discovery process.  The ability of CLS 
methods to accurately identify metabolites associated with group differences is evidenced 
by the fact that AUC values for all three CLS methods evaluated in this study were 
significantly increased above the null model.  Additionally, the significant increase in the 
AUC values attained via incorporation of weighting factors indicates that weighted 
methods can provide a significant improvement in discriminative marker discovery 
versus non-weighted least-squares. 
Weighting factors that maximize the importance of “clear” spectral regions will 
be increasingly useful as spectral alignment algorithms improve and bin sizes decrease or 
become altogether unnecessary.  While binning spectral regions is a useful tool in dealing 
with inter-individual alignment variability, it also masks spectral features that can serve 
to discriminate between metabolites in a given region (Stoyanova et al.., 2004b).  
Furthermore, since the algorithm described here is flexible and can deal with 
heterogeneous bin sizes, regions less affected by alignment problems can be evaluated at 
a high resolution, while more problematic regions can be grouped in arbitrary bin sizes, 
thereby maximizing the information gained. 
Experimentation with various parameter settings of the simulated datasets (data 
not shown) revealed the importance of the specific dataset in quantitatively evaluating the 
various weighting factors.  Therefore, an individual weighting factor will have varying 
strengths and weaknesses depending on the particular dataset in question.  Despite the 
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fact that no two NMR datasets are alike, an attempt was made to simulate what could be 
considered a typical NMR dataset.  It should be mentioned, however, that in the analysis 
of data from real samples different underlying biological processes will produce different 
data configurations and therefore are likely to require attention to different details in the 
data structure.  This fact further supports the concept that the use of specific weighted 
factors can help investigators to analyze their data more effectively. 
Furthermore, since there continues to be a great deal of active research in the field 
of data preprocessing, the described approach was implemented within a framework that 
accommodates such inquiries.  This model performs the least-squares fitting at a user 
defined level of spectral precision that need not be homogeneous within an individual 
subject.  Reference spectra data input is extremely flexible and can be derived from 
modeled data, spike-in analyses, or literature sources.  This can be an important 
consideration for metabolites that show strong pH dependence to peak shape and 
position. Though the model has been seen to be robust in the absence of baseline 
estimates, if desired (e.g. when estimating the protein contribution to the baseline of male 
mouse urine NMR data [Connor et al. (in preparation)], externally derived estimates of 
baseline can also easily be integrated into the reference spectra.   
In addition to the default non-negativity constraint, users can also choose to 
constrain the model to the upper limit of the data matrix (i.e. the model is prevented from 
over-explaining the data).  Typically in NMR datasets, there will be an unequal 
assignment confidence throughout the spectra, depending on prior knowledge, peak 
overlap and the degree of analytical confirmation of each component (2D homonuclear 
and heteronuclear NMR, fractionation, LC/MS confirmation, addition of standard).  The 
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described method allows users to experiment with the weighting factor used in the least-
squares fit.  Here, weighting factors that were a function of the number of compounds 
populating a particular spectral region or a function of the group variances were 
evaluated.  However, there are likely many other weighting factors that will prove useful.  
For example, it has been seen (data not shown) that a function of binwise correlations can 
also serve as an effective weighting factor.  Binwise correlations are of increasing interest 
in the field of metabolomics (Cloarec et al., 2005; Sandusky et al., 2005).  Furthermore, 
model fits can be restricted to subsets of the spectra either through manipulation of the 
input dataset or the spectral weighting. 
This work attempts to provide tools for the detection and assignment of group 
differences within a flexible, robust framework for metabolomics investigators to explore 
and analyze NMR data.  While traditional methods of NMR spectral analysis are 
extremely time-consuming, using the method described here, an investigator can perform 
a complete analysis in a matter of minutes.  Additionally, a successful analytical 
technique should provide investigators a broad scope of inference.  Since different 
datasets will have different structures, investigators are not limited to a predefined suite 
of weighting parameters.  The sole data input for LCModel is time-domain in vivo data 
and there is no user interaction in the data processing.  While there is a need for inter-
laboratory comparability, NMR data preprocessing is still an active area of research and it 
is advantageous for investigators to work within a well-defined, yet less stringent, 
framework of inquiry.  Furthermore, in agreement with the conclusions of Jansen et al. 
(2004), though in a different context, it has been demonstrated that the use of a weighting 
factor can provide an additional, more focused view of the data.  In addition, it is clear 
42 
 
 
that when working with some datasets, it may make the difference between successfully 
identifying a discriminative marker and missing it altogether.  The above described 
method provides a robust, flexible framework for compound level estimation.
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CHAPTER 3: Evaluation of NMR Deconvolution Algorithm for Individual Sample 
Estimates 
 
3.1 Summary 
This chapter is an extension of the work presented in Chapter 2.  This work was done in 
collaboration with Susan Connor, Jack Newton, Pascal Mercier, and David Chang. 
3.2 Introduction 
 The process of manually validating the change in a particular metabolite across 
treatment groups typically begins by investigating a region of the spectra that contains an 
isolated resonance from that metabolite.  Since the resonance is isolated, the biological 
signal is clear of obstruction and interpretation is straightforward.  The remainder of the 
metabolite signature is then investigated to provide further evidence for an accurate 
assignment.  The concept that information about metabolite levels is heterogeneously 
distributed through the spectra led to the hypothesis that weighted fitting would be of use 
(Chapter 2).  Specifically, that weighting spectral deconvolution based on metrics of how 
“crowded” spectral regions were, would improve estimated metabolite levels.   
 The work of the previous chapter describes the performance of a weighted 
deconvolution method for the discovery of differences (metabolites with different 
concentrations) between groups of complex NMR spectra.  It is also of interest to 
evaluate the ability of the algorithm to estimate metabolite levels at the individual sample 
level instead of identification of group differences.  Having metabolite estimates for 
individual samples allows investigators to evaluate the data with additional resolution and 
creates opportunities for exploration of covariation metrics (e.g. correlation coefficient). 
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3.3 Methods 
 To compare the performance of unweighted and bin-variance weighted 
deconvolution algorithms in estimating metabolite levels underlying complex NMR 
spectra, a number of simulation analyses were conducted  Using the Chenomx urine 
reference spectra library (184 metabolites) with a fixed bin width of 0.04 ppm, pseudo-
spectra were generated and individual metabolite levels were estimated.   
 Complex spectra were generated by multiplying normalized reference spectra 
(most intense peak = 1.0) from 92 of the library metabolites by a random variable drawn 
from the uniform distribution (U[0,1]).  Next, a certain proportion of metabolites were 
withheld from (0%, 5%, 10%, 15%, 20%) or added to (+100%) the reference library for 
use by the algorithm.  The metabolites in the reference library used by the algorithm, or 
the “known” metabolites, were thus 200%, 100%, 95%, 90%, 85%, and 80% of the 
underlying spectra.  The pseudo-spectra were then analyzed 10 at a time by both 
unweighted and variance weighted least-squares deconvolution and individual metabolite 
levels were estimated for individual samples (variance calculated across the 10 samples).  
This process was repeated 100 times for each percentage profile of “known” metabolites.   
 In Chapter 2, the relationship between bin variance and the “crowdedness” of a 
spectral bin is speculated.  In order to explore this relationship, the inverse of the bin 
variance of 10 pseudo-spectra (using the method described above, but with all 184 
metabolites) is investigated and compared to the number of metabolites with resonances 
found in that bin.
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3.4 Results/Discussion 
 The difference in performance between the weighted and unweighted method is 
visualized in a plot of the cumulative fraction of metabolites having a given absolute 
deviation of, or below, a particular value (Figure 3.1).  This figure shows that with a 
known reference library coverage of 95%, the unweighted algorithm estimated 80% of 
metabolites from 0.5 to 2.0 times the true underlying value (1.0x being exact estimation).  
Note that even with 100% and 200% reference library coverage only 10% 
(approximately) of metabolites had near exact estimates. 
 The relationship between the number of metabolites with a resonance in a 
particular bin and the inverse of the variance of that bin (Figure 3.2) suggests that there is 
a tendency for fewer metabolites in a bin to be indicative of a lower bin variance.  This 
leads to an increased weight (1/variance) for less crowded bins with no dependency on 
external databases.  This independence from external databases removes weighting 
metric bias potentially caused by the user selection (or availability) of metabolites in the 
reference spectral library.  The effect of this bias can be seen in Chapter 2 by the 
disappearance of the effectiveness of the 1/m weighting vector in the general simulation 
analysis. 
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Figure 3.1.  Cumulative fraction metabolites within absolute fold change (estimated/observed) in x-
axis. 
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Figure 3.2.  Relationship between inverse bin variance and the number of metabolite resonances in a 
given spectral region (bin).
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CHAPTER 4: Assignment of MS-based metabolomics datasets via compound 
interaction pair mapping  
 
4.1 Summary 
This chapter discusses a novel approach for assignment of MS-based metabolomics peaks 
and has been modified from an article accepted by the journal Metabolomics (Gipson et 
al., 2008) with permission from Springer Science and Business Media.  This work was 
done in collaboration with Dr. Kay Tatsuoka, Dr. Bahrad Sokhansanj, Dr. Rachel Ball, 
and Dr. Susan Connor.  The majority of the introductory material from this chapter is also 
located in Chapter 1, but has been reproduced here to provide the information in the 
original context.  Assignment of physical meaning to mass spectrometry (MS) data peaks 
is an important scientific challenge for metabolomics investigators.  Improvements in 
instrumental mass accuracy reduce the number of spurious database matches, however, 
alone this is insufficient for accurate, unique high-throughput assignment.  A method for 
clustering MS instrumental artifacts and a stochastic local search algorithm for the 
automated assignment of large, complex MS-based metabolomic datasets is presented.  
Artifact peaks and their associated source peaks are grouped into “instrumental clusters.”  
Instrumental clusters, peaks grouped together by shared peak shape in the temporal 
domain, serve as a guide for the number of assignments necessary to completely explain 
a given dataset.  Mass only assignments are refined through the intersection of peak 
correlation pairs with a database of biochemically relevant interaction pairs.  Further 
refinement is achieved through a stochastic local search optimization algorithm that 
selects individual assignments for each instrumental cluster.  The algorithm works by 
choosing the peak assignment that maximally explains the connectivity of a given cluster.  
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This methodology is demonstrated to provide a significant advantage over standard 
methods for the assignment of metabolites in a UPLC-MS diabetes dataset. 
4.2 Introduction 
Mass spectrometry (MS) methods are important data platforms for metabolomics 
investigators (Want et al., 2005).  A particular challenge of global metabolite profiling, 
whether using MS or nuclear magnetic resonance (NMR), is assignment of spectral peaks 
of interest (Kell, 2004).  Previously described informatics methods have been developed 
to help to reduce this major bottleneck, although most of the approaches have not yet 
been fully validated in the context of analytically confirmed assignments.  The proposed 
solutions have employed mass only database search methods (Smith et al., 2006), refined 
mass database search methods utilizing isotopic patterns (Kind and Fiehn, 2006), mass 
spectral libraries (Kopka et al., 2005), and ab initio mass transformation pairs (Breitling 
et al., 2006a; 2006b) for the putative assignment of metabolites in high-throughput 
metabolomic datasets.   
Correlation networks of the assigned components of metabolomic datasets have 
been suggested for the construction of metabolic networks (Arkin et al., 1997, Steuer et 
al., 2003a).  Although metabolic neighbors in shared biochemical pathways have been 
observed to be significantly correlated, evaluations of modeled and experimental data 
suggest that observed correlation networks do not “necessarily” reflect underlying 
pathway structure and correlations often exist that are inexplicable given current 
biochemical knowledge (Steuer et al., 2003a; 2003b; Steuer, 2006).  Although, it is 
recognized that not all metabolite correlations “necessarily” provide information useful 
for assignment within the context of existing biochemical pathways, those correlations 
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which intersect with described biochemical interactions can likely be used to inform the 
assignment of MS data peaks.  In other words, while current understanding of 
biochemical interactions is incomplete and cannot fully characterize the pathway 
relationships underlying observed metabolite correlations, it is hypothesized that existing 
biochemical knowledge provides useful information for the assignment of unknown 
compounds in large metabolomic datasets.   
In a recently described method for ab initio metabolic network prediction, 
investigators present a method for assignment of putative metabolite transformation pairs 
using ultra high mass accuracy MS methods coupled with mass searches focused on 
metabolic transformations (Breitling et al., 2006a).  The method identifies a series of 
putative ion reaction pairs by mapping peak mass differences to biochemical 
transformation reactions.  According to the authors, one of the benefits of this analysis is 
that their network links are directly associated with known chemical reactions, exceeding 
the level of descriptive connectivity of metabolite correlation networks.  Here, a method 
is presented that provides explicit biological meaning to observed data relationships 
which can provide insight into the assignment of features in MS-based datasets. The 
method is intended to be a useful assignment tool, even for lower mass accuracy 
instruments that are in common use.  However, improving the mass accuracy will likely 
improve obtained results. 
A recent review of MS-based metabolomics describes the current usage of 
biochemical databases as a means to infer biological function of previously identified 
metabolites (Dettmer et al., 2007).  Applications utilizing existing biochemical pathways 
include visualization (Mendes, 2002) and metabolic flux analysis (Forster et al., 2002).  
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However, a global, systematic intersection of metabolite correlation pairs with a database 
of biochemical interaction pairs has not yet been described.  Here, a method is presented 
which can select likely metabolite candidates and increase confidence in metabolite 
assignment.  Specifically, the aim is to identify metabolites in an ultra performance liquid 
chromatography (UPLC)-MS dataset by mapping peak interaction pairs (significantly 
correlated peak pairs) onto interaction pairs from the Kyoto Encyclopedia of Genes and 
Genomes (KEGG) (Kanehisa et al., 2006) using mass matching.  Anticipated benefits of 
this methodology include robustness to varying instrumental mass accuracy and 
immediate placement of annotated metabolites into an explicit biological context. 
An additional challenge of MS-based metabolomics assignment is the 
differentiation between mass differences associated with in vivo transformation and those 
which are artifacts of MS instrumentation.  It is necessary to identify artifactual peaks 
(e.g. fragments, oligomers) to avoid assigning biological meaning to highly correlated 
peak pairs which are measurements of the same metabolite.  To avoid annotation of 
instrumental artifacts, peaks are grouped which appear to share the same compound 
source into “instrumental clusters.”  This has previously been performed manually 
through visual inspection of data peaks.  In this study, the instrumental clustering process 
is automated and integrated it into the assignment algorithm.    
A previous study (Breitling et al., 2006a) attempted to minimize the assignment of 
instrumental artifacts using a refined, a priori set of biochemically meaningful mass 
differences.  Here, peaks with shared temporal peak shapes are clustered to distinguish 
between instrumental and biological peak relationships.  To this end, and to aid the 
development of the automated assignment tool, an evaluation of both (i) an artificial 
52 
 
 
biofluid matrix consisting of metabolite standards, and (ii) urine from diabetic and 
healthy mice was undertaken.  Findings are validated by analytical confirmation of the 
metabolite identity. 
4.3 Materials and Methods 
4.3.1 Experimental Data 
A mixture of 21 metabolite standards with mixed adduct, oligomer, and fragment 
formation profiles was used to evaluate the automated instrumental clustering technique.  
A dilution series (1:1, 1:2, 1:10, 1:100) of the mixture was analyzed with UPLC-MS (5 
technical replicates for each dilution), and select metabolites were further profiled with 
MS/MS experiments. 
Urine samples were collected from adult, male db/db and db/+ mice from The 
Jackson Laboratory (Bar Harbor, Maine) at 8, 12 and 20 weeks of age (10 db/db and 10 
db/+ mice per collection event).  A 50 µL aliquot of urine supernatant was diluted to 200 
µL with HPLC-grade water prior to infusion in the chromatographic column.  For more 
detail about the analyzed datasets, see Section 4.6. 
4.3.2 Instrumentation 
The data used in this study were positive polarity UPLC-MS datasets.  
Chromatographic separations were achieved using an ACQUITYTM C18 (100x2.1mm 
i.d., 1.7µm particle size) column (Waters Corporation, Milford, USA) on an 
ACQUITYTM UPLC system (Waters).  Mass spectrometry was performed on a Waters 
LCT PremierTM (Waters MS Technologies, Manchester, UK) orthogonal acceleration 
time-of-flight (oa-TOF) mass spectrometer operating in W optics mode.  
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 To assess the ability of the algorithm to accurately assign UPLC-MS data peaks, it 
was necessary to confirm the resulting assignments using standard analytical chemistry 
procedures.  These included UPLC-MS/MS and spiking experiments of authentic 
metabolites.  These experiments were performed on diluted urine and standard solutions 
using a Waters Q-Tof PremierTM (Waters MS Technologies, Manchester, UK) 
quadrupole, orthogonal acceleration time-of-flight tandem mass spectrometer operating 
in V optics mode.  Section 4.6 contains more detail regarding the instrumentation. 
4.3.3 KEGG Database 
Here, “biochemical interactions” is defined as either primary or secondary KEGG 
reactions, enzymes, or pathways.  Primary interaction pairs are those in which both 
metabolites participate in a particular reaction, share an enzyme, or are part of the same 
pathway.  Secondary reactions are those in which both metabolites share a common 
reactant.  Secondary enzyme interactions are those in which two compounds can be 
linked by way of a third compound with which they each share associations with a 
common enzyme.  Figure 4.1 provides graphical examples of these relationships.  
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Figure 4.1.  Reaction diagrams from KEGG (Kanehisa, et al., 2006).  Primary reaction pairs are any 
two compounds in a common reaction (e.g. C00019 and C00388 in subgraph a).  Primary enzyme 
pairs are any two compounds with a common enzyme (e.g. C00388 and C00141 in subgraphs b and c, 
respectively).  Note that primary enzyme interactions often overlap with primary reactions (e.g. 
C00019 and C000388 are linked by both a primary reaction and an enzyme interaction in subgraph 
a).  Secondary reaction pairs are two compounds which share a reaction with a common third 
compound (e.g. C00019 and C00024 linked by reactions with C00388 in subgraphs a and b, 
respectively).  Secondary enzyme pairs are two compounds which share an enzyme with a common 
third compound (e.g. C00019 and C000141 linked by a shared enzyme with C00388, all subgraphs 
necessary to create link).  Primary pathway pairs are any two compounds found in an individual 
KEGG pathway (e.g. C00141 and C00024 in the Valine, Leucine and Isoleucine Degradation 
pathway – see Figure 4.5).
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 The COMPOUND section (Goto et al., 1998) of the KEGG LIGAND database 
(release 29.0) was used to define the reaction and enzymatic interaction pairs.  
Ubiquitous compounds with highly promiscuous interaction profiles (i.e.  H+, H20, O2, 
CO2, NH3, A(M,D,T)P, NAD(+,H,P,PH), FAD, UDP) were removed to limit the number 
of spurious secondary interactions.  KEGG metabolites with either coenzyme-A (CoA) 
conjugates or acyl carrier protein (acp) conjugates were modified by substitution with 
OH, glycine, and glycine+O to account for biotransformation prior to excretion in urine.  
These substitutions were made based on prior experimental findings (data not shown). 
4.3.4 Instrumental Clustering/Interaction Pair Identification 
 Following peak-picking with xcms (Smith et al., 2006) and intensity 
normalization, a series of correlation analyses were conducted with the aim of identifying 
interaction pairs.  A preliminary list of peak interaction pairs is populated through 
significance thresholding of a modified correlation analysis (Pearson’s) of the log 
transformed total peak intensity across all individuals.  Peak interaction pairs were 
defined as those peaks with significant correlation coefficients (Benjamini and Hochberg 
correction, FDR = 0.001).  To eliminate the masking effect of a large group difference, 
prior to this correlation analysis, the mean groupwise intensity value was subtracted from 
the values of individual group members.   
 In datasets in which the experimental variable leads to dramatic biological 
alterations, within-group variation is often small in comparison to group differences (e.g. 
db/db versus db/+).  A calculated correlation coefficient between two independent 
variables displaying a large group difference is essentially an indicator of shared 
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directional change and provides no information concerning more discrete co-regulatory 
relationships.   
Peaks are grouped into the same instrumental cluster if they were previously 
identified as a peak interaction pair and they have similarly shaped temporally 
overlapping peaks.  Peak shape similarity was measured with a second correlation 
analysis and restricted to peak pairs with a minimal number (5) of overlapping scans.  
The correlation coefficient (Pearson’s) is calculated for these peak pairs (across all 
individuals and time points) as a measure of peak shape similarity.  Peaks are grouped 
into the same instrumental cluster if they were previously identified as a peak interaction 
pair and they have a peak shape correlation exceeding a threshold value.  The peak shape 
correlations were calculated across all scans and all samples.  This presents the problem 
of treating auto-correlated temporal data as independent replicates.  To avoid this, a 
correlation significance threshold (Bonferroni adjusted) was employed based strictly on 
the number of true replicates.  In order to account for the possibility that a defined peak is 
actually a composite of multiple peaks, an individual peak can belong to multiple 
instrumental clusters.  Each cluster is characterized by every member meeting correlation 
significance criteria with every other member. 
Instrumental pairs are filtered from the peak interaction pair list to remove peak 
relationships caused by instrumentation to be interpreted biologically.  Finally, the 
intersection between peak interactions and biochemical interactions is delineated through 
mass mapping (assuming a mass accuracy of 25 ppm for m/z > 200 and 0.005 Da for m/z 
≤ 200).   
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4.3.5 Optimization Algorithm 
The process of identifying the intersection of peak interaction pairs and 
biochemical interaction pairs leads to a list of putative assignments in which multiple 
peaks can have the same assignment and individual peaks can have multiple assignments.  
In order to provide further refinement of the list of putative assignments, a stochastic 
local search algorithm is performed to assign unique assignments to peaks associated 
with instrumental clusters through maximizing the total strength of peak interaction pairs 
explained.  Here, the strength of an individual peak interaction is a function of the 
specific biochemical interaction(s) employed to explain it.  The strength of each 
biochemical interaction type was quantified with a weight based on the probability [-
log(P)] of occurrence in the modified (accounting for biological transformation) KEGG 
database.  In cases where given interaction has multiple biochemical interaction types, the 
strength of that interaction would be the sum of the weights for all interaction types.  
Following an extensive analysis of the –log(P) weighting method, additional 
optimizations were performed in which: 1.) All interaction types were included and 
metabolite-metabolite interactions were scored as the sum of equally weighted interaction 
types; 2.) All interaction types were included and all metabolite-metabolite interactions 
were scored equally, regardless of interaction type contribution; 3.) Only 2o interactions 
were included and all metabolite-metabolite interactions were scored equally, regardless 
of interaction type contribution; and 4.) Only 1o interactions were included and all 
metabolite-metabolite interactions were scored equally, regardless of interaction type 
contribution. 
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 The search algorithm is initialized with each instrumental cluster being randomly 
associated with either a putative assignment or no assignment.  Each cluster is then 
iteratively evaluated in a random order, and cluster assignments are made based on which 
putative identification maximizes the overall connection strength within the context of all 
other current assignments.  The algorithm is terminated following three evaluations of 
each cluster (Figures 4.6 & 4.7).   
The KEGG database is an incomplete characterization of biochemical 
interactions.  It was of interest to identify consensus assignments through successive 
perturbations of the KEGG database prior to optimization and evaluate the frequency of 
individual assignments.  This will provide investigators with a distribution of assignments 
for each cluster, and therefore provide an estimate of confidence in a particular 
assignment.  In order to achieve this, the interaction weighting matrix was sampled (80% 
of total interactions) prior to executing the search algorithm.   
Since the optimization algorithm is stochastic, it is run several times and putative 
assignments can be ranked based on occurrence frequency.  Output from the assignment 
optimization algorithm is structured as a list with the same number of elements as there 
are instrumental clusters.  Each list element is comprised of a list of putative assignments, 
for a particular instrumental cluster, ranked by frequency of occurrence.  Section 4.6 
contains more detail about the optimization algorithm.   
4.4 Results and Discussion 
4.4.1 Instrumental Clustering 
There are two types of peak relationships that are of interest in this study:  peaks 
originating from different parent compounds that are biochemically related in vivo and 
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instrumental artifacts that are related to a common parent compound.  The importance of 
characterizing the second type of peak relationship is that this knowledge can be used to 
restrict assignment to one explanatory peak per cluster and hence act as a filter for 
biologically meaningless mass-mass pair interactions. 
Comparison of instrumental clusters generated through the automated technique 
and traditional visual inspection reveals a large overlap between the two methods. The 
clustering software typically identifies additional cluster members not discovered through 
visual inspection.  To demonstrate the functionality of the clustering algorithm, the mass 
spectra of 5-hydroxytryptophan (5-HTP) and phenylacetylglutamine (PAGn) were 
extracted from the dataset and examined in closer detail.  In-source adducts, oligomers, 
and fragments were assigned using a 25 ppm mass error for all ions above 5% intensity of 
the base peak.  Fragmentation was subsequently confirmed by MS/MS.   
Visual inspection of the extracted mass spectra for 5-HTP and PAGn from the 
LC-MS dataset of the standard mix identified 3 mass peaks associated with 5-HTP (m/z= 
162.0555, 204.0661, 221.0926 [M+H] +) and 9 mass peaks associated with PAGn (m/z= 
84.0442, 130.0504, 248.0923, 265.1192 [M+H]+, 287.0999, 288.1029, 551.2028, 
567.1771, 568.1815).  The automated technique identified individual instrumental 
clusters for both the 5-HTP and PAGn peaks ([M+H]+).  The 5-HTP cluster contained 2 
of the 3 mass peaks identified by visual inspection but lacked the 162.055 m/z fragment.  
The omission of the 162.055 m/z fragment from the 5-HTP cluster was due to non-
optimal peak picking conditions for this peak.  Since it was absent from the peak-picked 
dataset, this peak will not be found in the 5-HTP cluster.  There was also an additional 
peak in the 5-HTP cluster that was not observed initially in the visual analysis. The PAGn 
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cluster contained all 9 mass peaks identified by visual inspection, plus 12 additional 
peaks.  Follow-up evaluations of the 5-HTP and PAGn clusters revealed that all peaks 
clustered together by the automated method did indeed share a common parent 
metabolite. 
Revisiting the visual inspection revealed that each of the additional peaks which 
clustered with 5-HTP (m/z= 243.0748) and PAGn (m/z= 83.0611, 129.0657, 136.0760, 
247.1076, 266.1254, 552.2057, 553.1923, 554.1958, 569.1833, 583.1511, 591.1582, 
592.1619) were real adducts, oligomers, or fragments.  However, they were either outside 
of the 25 ppm mass window or below 5% base peak intensity.  A graphical representation 
of the time evolution of the peaks associated with the PAGn cluster (Figure 4.2) 
demonstrates the ability of the method to identify overlapping peaks with similar 
temporal profiles. 
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Figure 4.2.  Plot of the temporal profile of peaks (from an individual subject) assigned to the 
instrumental cluster associated with PAGn.  Peaks identified through visual inspection are labeled 
(m/z values). 
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This method is completely independent of assumptions regarding acceptable and 
non-acceptable transformations, whether biochemical or instrumental.  This is important 
given that within the mass domain, biochemical and instrumental changes can appear 
identical.  The fact that the alteration of physiochemical properties due to biological 
rather than instrumental transformations will typically lead to alterations in column 
retention characteristics is helpful.  As such, any transformations existing prior to entry 
into the ion source and MS would be expected to have different temporal profiles. 
4.4.2 Interaction Pair Identification 
The KEGG database yields 8,438 primary reactions, 28,104 primary enzyme 
interactions, 73,182 primary pathway interactions, 393,325 secondary reactions, and 
697,338 secondary enzyme interactions describing the relationships between 4,016 
metabolites.  Following preliminary assignment of the data with the KEGG database, the 
output is organized into 6 data files with linked identifiers.  These data files can be 
imported into a database and easily queried for either mass only assignment predictions, 
or for peak/biochemical interaction intersection assignment predictions.  Additionally, 
these data files serve as the input for the stochastic local search optimization algorithm. 
 The data analysis resulted in the extraction of 2,767 data peaks, 1,262 
instrumental clusters, 218,895 peak interaction pairs (212,573 excluding pairs in same 
instrumental cluster), 3,164 putative mass only assignments, and 17,349 putative 
peak/biochemical interaction intersection assignments (11,649 unique intersection 
assignments).  
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 Through various stages of this methodology, the KEGG database is either 
modified or filtered to meet specific needs.  Each time the KEGG database is altered, the 
possibility exists that the distribution of the various interaction types will change.  The 
characteristics of the initial KEGG database, compared to the first (substitution of 
biotransformation products) and second (filtration via mass matching) alterations the 
database vary little (1o Reaction=0.69-0.71%, 1o Enzyme=2.3-2.9%, 1o Pathway=5.5-
6.1%, 2o Reaction =31.9-32.8%, 2o Enzyme=57.8-58.9%).  This indicates that the 
database alterations have not affected the underlying database characteristics.  However, 
the third alteration (filtration via correlation pair intersection) leads values of 1.7% (1o 
Reaction), 5.4% (1o Enzyme), 7.5% (1o Pathway), 29.3% (2o Reaction), and 56.1% (2o 
Enzyme).  The increase of the primary interactions (1.34-2.40 fold) and decrease of 
secondary interactions (0.92-0.95 fold) indicates that the primary interactions have an 
increased prevalence in the correlation filtered database and therefore, primary 
interactions are likely more predictive of significant correlations. 
4.4.3 Optimization Algorithm 
Network connection strength, based on the biochemical interaction types acting as 
network edges, is calculated using the modified (including transformations) KEGG 
database.  Shared pathways were more common (5.8%) than shared enzymes (2.9%), 
which in turn, were more common than shared reactions (0.7%), and secondary 
interactions (reaction chain 32.8%; enzyme chain, 57.8%) were far more common than 
primary interactions.  Assignment alterations performed by the algorithm strictly increase 
the overall connection strength of the network (Figure 4.7), and the impact that this has 
on the interaction sub-network associated with Trimethylamine N-oxide can be seen in 
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Figure 4.3.  The edges in this figure represent the existence of a significant correlation 
between members of different clusters concurrent with assignments within a shared 
biochemical interaction pair.  Prior to unique assignment, the sub-network is highly 
connected due to the inclusion of all putative assignments per cluster.  Once unique 
assignments are made for each cluster, edges associated with discounted assignments will 
be lost.  The goal of the stochastic local search algorithm is to maximize not just the 
number of connections in the global network, but the strength of the connections as well.  
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Figure 4.3.  Connectivity plot of sub-network associated with Trimethylamine-N-oxide (cluster 9).  left. Multiple assignments per cluster allow for 
maximal connectivity. middle. Random initialization with unique assignments does a poor job of explaining peak interactions. right. Assignment with 
cluster specific, top-ranked metabolites yields a highly connected sub-network.
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The ability of the algorithm (denoted “alternative model”) to outperform a mass 
only search of the KEGG database (“null model”), and an interaction intersection search 
of the KEGG database (“filtered model”) was assessed.  To do so, lift curves (Witten and 
Frank, 2000) were constructed representing the expected number of correctly assigned 
validation peaks versus the total number of assignments examined (Figure 4.4).  Putative 
assignments from the algorithm, employing –log(P) weighted scoring, were first sorted in 
descending order with respect to the number of times an assignment was proposed (over 
100 iterations of the search algorithm) irrespective of cluster representation.  For this 
reason an individual assignment may occur more than 100 times.  Following the sorting 
procedure, the assignments were iteratively checked for accuracy and a cumulative total 
of correct hits was enumerated.  The performance of both the filtered and null models 
was computed with a random selection model of the correct hits from the pool of putative 
assignments.  The non-linearity of the performance of the filtered and null models (Figure 
4.4) occurs because there are multiple (3) KEGG entries (glutamate, L-glutamate, or D-
glutamate) that can explain the glutamate clusters.
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Figure 4.4.  Lift curve comparison of validated peak assignment with unfiltered KEGG mass search 
(null), KEGG mass search following interaction intersection (filtered), ranked assignments through 
stochastic local search algorithm (alternative). 
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The lift curve (Figure 4.4) demonstrates both the utility of restricting mass only 
searches to highly validated biochemical interaction pairs (filtered model), as well as the 
improved performance achieved through ranking filtered assignments with the stochastic 
local search algorithm.  The comparison reveals that, to identify the correct assignment 
for the clusters associated with the 9 validation compounds, an investigator would need to 
evaluate 195, 101, and 41 putative assignments using a mass only search, an interaction 
filtered search, and an optimized search, respectively.  Thus, using this approach provides 
a nearly 2- and 5-fold reduction in the number of putative assignments necessary to 
evaluate using an interaction filtered search and an optimized search, respectively.  Table 
4.1 summarizes the assignment results from the optimization algorithm, as well as the 
number of putative hits (filtered and null model), for the clusters associated with 9 
validated metabolites.  A comparison to alternative scoring procedures indicates that the 
–log(P) weighted scoring performs favorably well (Table 4.2).
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Table 4.1.  Assignments produced for the instrumental clusters associated with the 9 validation 
metabolites    
 
1st Ranked 2nd Ranked 
Instrumental 
Cluster Correct Assignment Putative Annotation  
(KEGG ID) %Hits 
Putative Annotation 
(KEGG ID) %Hits 
Filtered 
Assignments 
Null 
Assignments 
965 
5-Hydroxy-L-
tryptophan 
 
5-Hydroxy-L-tryptophan 
(C00643) 100 NA NA 1 3 
68 Adenosine  
Adenine 
(C00147) 94 
Adenosine 
(C00212) 5 5 11 
64 Creatine  
Creatine 
(C00300) 94 
3-Guanidinopropanoate 
(C03065) 6 2 5 
470 Hippurate  
(R)-4'-Phosphopantothenoyl-
L-cysteine 
(C04352) 
71 Phenylacetic acid (C07086) 14 40 80 
138 Hippurate  
D-Fructose 
(C00095) 38 
Hippurate 
(C01586) 33 26 60 
20 Hippurate  
Benzoate 
(C00180) 37 
D-Fructose 
(C00095) 22 33 74 
72 Hippurate  
Phenylacetic acid 
(C00582_-CoA:+OH) 36 
Phenylacetic acid 
(C07086) 34 39 78 
501 Hippurate  
Benzoate 
(C00180) 35 
Phenylacetic acid 
(C00582_-CoA:+OH) 27 52 101 
521 Hippurate  
D-Glucose 
(C00031) 31 
Hippurate 
(C01586) 26 26 61 
502 Hippurate  
Phenylacetic acid 
(C07086) 29 
Benzoate 
(C00180) 28 46 92 
107 L-Carnitine  
L-Carnitine 
(C00318) 100 NA NA 1 5 
89 L-Glutamate  
L-Glutamate 
(C00025) 97 
Hydroxypropanoylglycine 
(C00100_-CoA:+glycine+O) 3 11 14 
227 Pantothenate  
Pseudoecgonylglycine 
(C12450_-CoA:+glycine) 83 
Pantothenate 
(C00864) 17 3 10 
217 Phenylacetylglycine Phenylacetylglycine (C05598) 28 
Phenylacetylglycine 
(C00582_-CoA:+glycine) 20 20 37 
508 Phenylacetylglycine  
Phenylacetylglycine 
(C00582_-CoA:+glycine) 28 
Phenylacetylglycine 
(C05598) 18 20 38 
7 Phenylacetylglycine  
Phenylacetylglycine 
(C00582_-CoA:+glycine) 26 
5-
Hydroxyindoleacetaldehyde 
(C05634) 
23 22 40 
161 Phenylacetylglycine Phenylacetylglycine (C05598) 23 
Phenylacetylglycine 
(C00582_-CoA:+glycine) 20 18 34 
9 
Trimethylamine N-
oxide 
 
Trimethylamine N-oxide 
(C01104) 99 
1-Aminopropan-2-ol 
(C05771) 1 3 3 
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Table 4.2.  Performance of the search algorithm using different weighting schemes.  Metabolite-
metabolite interaction pairs are scored by the sum of the weights of each type of interaction found.  
 
Weighting Performance 
1o Reaction 1o Enzyme 1o Pathway 2o Reaction 2o Enzyme Fraction Correct 
# Putative 
assignments 
1 1 1 1 1 8/9  46  
1* 8/9  51  
0 0 0 1* 8/9  48 
1* 0 0 9/9 69 
4.96 3.54 2.85 1.11 0.55 9/9 41 
*an individual weight is attributed if any of the interaction types are found
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 It should be noted that there are various features within the framework presented 
here that an individual investigator may want to explore.  For instance, the association of 
peaks into interaction pairs can be manipulated through various means, including: 
changes in data normalization techniques; significance thresholding; or other significance 
criteria.  As an example, an analysis was performed in which peak correlations were 
calculated in a group-specific manner (i.e. a coefficient for db/db and a separate 
coefficient for db/+), and interaction pairs were defined by a significant relationship in 
either group.  By altering the definition of interaction pairs in this way, the number of 
significant peak correlations is reduced from 218,895 to 155,760, with 115,972 common 
pairs.  Furthermore, for this dataset, it was found that the group-specific interaction pair 
criteria improved the performance of the method.  To identify the correct assignment for 
the clusters associated with the 9 validation compounds, an investigator would need to 
evaluate 184, 87, and 24 putative assignments using a mass only search, an interaction 
filtered search, and an optimized search, respectively.  Investigators using this assignment 
method should be aware that there is a trade-off between statistical power (allowing for 
biologically altered metabolic relationships via independent correlation calculation will 
reduce the degrees of freedom) and inferential scope (requiring different biological states 
to retain a particular relationship will necessarily narrow the data interpretation).  
A recent study evaluated content differences between several popular chemical 
databases (Kind and Fiehn, 2006) and came to two conclusions with respect to KEGG:  
(1) restricting automated mass spectra assignments to KEGG database searches is 
insufficient due to representation of only a limited number of potentially measured 
metabolites and (2) KEGG assignments may be more informative (when available), 
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specifically because of the focus on common biochemical pathways.  Given these 
findings, the use of the interaction pair mapping assignment is suggested only within the 
context of the quality of existing biochemical interaction databases.  Since current 
pathway databases are far from comprehensive, the proposed method should not be 
considered in isolation.  Rather, this method provides high quality assignments for a 
subset of the whole metabolome.  Additionally, by implementing a separation technique 
(LC) prior to MS analysis the capacity for the identification of instrumental fragments, 
adducts, and oligomers has been improved.  As biochemical interaction databases 
increase in size and quality, the integration of empirical peak relationships (e.g. data 
correlates), database mass searches, and validated biochemical interactions, will play a 
greater role in the assignment and interpretation of high-throughput MS-based 
metabolomic studies.        
4.5 Concluding Remarks 
 The need for techniques to complement mass only database assignment is driven 
by both the limited mass accuracy of instruments currently in use as well as the analytical 
constraint that mass alone is insufficient for assignment verification.  Here, the utility of 
accurately clustering instrumental artifacts and using a priori biochemical interaction 
data is demonstrated.  The ability to quantitatively segregate the quality of assignments 
(within the context of available biochemical pathway data) allows for the successful 
interpretation of large scale metabolomic datasets, and it is a valuable, time-saving tool 
for guided analytical verification of metabolite assignments.   
There is currently no standard instrumental setup used in MS-based 
metabolomics.  Since there are a wide variety of instruments and hyphenated techniques 
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used in MS-based metabolomics, the characteristics of the output should be taken into 
consideration when evaluating the utility of the described methods.  For example, 
investigators not using a separation technique prior to MS analysis will be unable to use 
the clustering algorithm described here, since it is dependent upon temporally resolved 
data and a well defined peak shape.  Nevertheless, assignment of all MS-based 
metabolomics datasets should be aided by the incorporation of interaction pair mapping.    
The integration of dataset independent biochemical information increases the 
accuracy of metabolite assignment, even at low mass accuracy (25 ppm).  Furthermore, 
biochemical pathway information will increase in value as biochemical databases grow 
and the quantity of validation data increases.  Additionally, an investigator can combine 
this automated assignment method with other data types (e.g. NMR metabolic profiling 
data, microarray) to improve and expand the current capabilities.  Although presented in 
isolation, this method can easily be integrated with other methods (e.g. isotopic pattern 
matching, mass spectral library queries, ab initio mass transformation pair matching) 
within a comprehensive assignment framework. 
4.6 Supplementary Material 
4.6.1 Diabetes Dataset 
All in-life experiments were conducted using adult, male db/db and db/+ mice 
from The Jackson Laboratory (Bar Harbor, Maine). All animals arrived at 4 weeks of age 
and were quarantined for 1 week. They were housed in groups of five on a 12:12-hour 
light-dark cycle and at 23 ± 2°C and had access to standard chow pelleted diet (Purina 
5001; TestDiet, Richmond, IN) and water ad libitum.  Urine was collected at 8, 12 and 20 
weeks of age from 10 db/db and 10 db/+ mice. For the 6 hour period of sample 
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collection, animals were transferred to metabolism cages (designed specifically for the 
separate collection of urine and feces) and given free access to water.  
Urine samples were collected over ice into collection pots that contained 1% 
azide.  The frozen mouse urine samples were allowed to thaw at room temperature prior 
to analysis. A 50 µL aliquot of urine supernatant was diluted to 200 µL with HPLC-grade 
water.  
4.6.2 UPLC -MS and -MS/MS 
HPLC-grade water and acetonitrile was purchased from Fisher Scientific 
(Loughborough, UK). Spectroscopic-grade formic acid and leucine enkephalin was 
purchased from Sigma–Aldrich (Poole, UK), and analytical-grade formic acid was 
purchased from BDH (Poole, UK).  
The ACQUITYTM C18 column was maintained at 40°C and eluted using a 10 min 
gradient (A=0.1% aqueous formic acid and B=acetonitrile 0.1% formic acid) at a flow 
rate of 500 µL/min. The gradient steps were:  0.0–0.5 min = 99.5% A; 0.5–7.5 min = 
99.5–80.0% A; 7.5-8.5 min = 80.0–0.5% A; 8.5–8.8 min = 0.5% A; 8.8–9.0 min = 0.5-
99.5% A; 9.0–10.0 min = 99.5% A.  A 20 µL aliquot of sample (i.e. diluted mouse urine, 
standard mixture) was injected directly on to the column and the column eluent was 
introduced directly in to the MS source.  
The LCT PremierTM (MS) desolvation gas was set to 800 L/h at a temperature of 
400°C, the cone gas set to 50 L/h, and the source temperature set to 120°C. The capillary 
voltage and cone voltage were set to 3000 and 50V respectively. The data acquisition rate 
was set to 150 ms, with a 50 ms inter-scan delay using dynamic range enhancement 
(DRE). All analyses were acquired using lock spray.  Leucine enkephalin was used as the 
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lock mass (m/z 556.2771) at a concentration of 50 ng/mL and flow rate of 50 µL/min. 
Data were collected in centroid mode from m/z 50–1000 with a lock spray measurements 
every 5 s, and data averaging over 10 scans. 
 The Q-Tof PremierTM (MS/MS) desolvation gas was set to 800 L/h at a 
temperature of 400°C, the cone gas set to 50 L/h, and the source temperature set to 
150°C. The capillary voltage and cone voltage were set to 3500 and 25V respectively. 
The data acquisition rate was set to 250 ms, with a 100 ms inter-scan delay using 
dynamic range enhancement (DRE). Where appropriate, MS/MS data were generated 
using collision induced dissociation (CID), with argon as the collision gas (0.35 mL/min) 
using a collision energy ramp of 10-30eV. A lock mass of leucine enkephalin at a 
concentration of 250 ng/mL, in 50:50 methanol:water, was employed with an infusion 
rate of 50 µL/min via the lock spray interface. Data were collected in centroid mode from 
m/z 50-1000 with a lock spray as above. All UPLC conditions were as described above. 
4.6.3 Peak Picking and Preprocessing 
Peaks were extracted from the UPLC-MS data using xcms (Smith et al., 2006).  
For this analysis, no retention time correction was employed, and the default initialization 
parameters were used with the exception of the full width at half maximum (fwhm), 
bandwidth (bw), and signal to noise threshold (snthresh).  Based on empirical 
observations, both fwhm and bw were changed to 5 scans.  The snthresh parameter was 
left as default (10) for the diabetes dataset analysis, but changed to 80 for the standard 
mixture analysis.  The resultant output from xcms was 2 data matrices (intensities x 
samples), describing the total peak intensities (1 intensity value per peak-sample) and the 
peak shape (1 intensity value per scan-peak-sample). 
76 
 
In order to normalize the data, first, the peaks were ranked with respect to the 
total intensity level (all individuals summed).  Next, the normalization factor was 
calculated as the inverse of the sums of the individual sample intensities of the middle 
80% of the ranked peaks.  The intensity levels for each sample were normalized through 
multiplication with the individual normalization factor. 
4.6.4 Peak Assignment 
The local search algorithm is initialized with each instrumental cluster being 
assigned either a random assignment or no assignment, with probability equal to the 
inverse of the number possible assignments plus 1.  Assignment is strictly performed for 
one peak per cluster.  During optimization, if a particular instrumental cluster has no 
assignments which can contribute to an increased score, the same random selection used 
for initialization will be employed. Commonly, assignments are encountered which can 
increase the score, but have been previously assigned to another peak.  In these instances, 
the score will be recalculated after the previously assigned peak is randomly reassigned.  
If the score remains improved, the reassignment holds and the current instrumental 
cluster is permitted to take the assignment.  If the score is not improved, the previous 
assignment holds and the assignment is disallowed for the current instrumental cluster.  
The search algorithm completed 100 iterations of 3-fold cluster optimizations for >500 
clusters in approximately 8 hours on a PC running Windows XP with a 2.80 GHz 
Pentium 4 processor and 1 GB of RAM.   
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Figure 4.5.  KEGG Valine, Leucine and Isoleucine Degradation pathway chart (Kanehisa, et al., 
2006).  Any two metabolites found in this pathway (or other pathway) are designated as having a 
primary pathway biochemical interaction.  
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Figure 4.6.  Flow diagram representation of the stochastic local search network optimization 
algorithm.  Initialization – All peak clusters are randomly attributed unique metabolite assignments, 
creating a network of assignments (nodes) and interactions (edges).  Cluster optimization – each 
cluster is individually evaluated (random order) and the assignment that maximizes the network 
score is selected.  An individual network optimization ends once each cluster has been evaluated 3 
times.  Network optimization is repeated 100 times.
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Figure 4.7.  Average score (100 runs) +/- 2 standard deviations of interaction networks as the local 
search algorithm progresses.  Arrows indicates the regions on the curve at which point all 521 
clusters have been evaluated (random order).  The algorithm was terminated after 3 post-
initialization evaluations due to reduced improvements in score.
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CHAPTER 5: Metabolomics of a Murine Model of Type 2 Diabetes  
 
5.1 Summary 
 This chapter discusses the technical and biological findings from a series of 
metabolomics datasets collected from a diabetic mouse model and has been modified 
from an article in preparation (Gipson et al., in preparation).  This work was done in 
collaboration with Dr. Kay Tatsuoka, Dr. Rachel Ball, Dr. Bahrad Sokhansanj, Dr. 
Michael Hansen, Dr. Terrence Ryan, Mark Hodson, Dr. Brian Sweatman, and Dr. Susan 
Connor.  The majority of the introductory material from this chapter is also located in 
Chapter 1, but has been reproduced here to provide the information in the original 
context.  Here, a multi-platform (1H NMR, LC-MS, microarray) investigation of 
metabolic disturbances associated with the leptin receptor defective (db/db) mouse model 
of type 2 diabetes using novel assignment methodologies is described.  For the first time, 
several urinary metabolites were found to be associated with diabetes and/or diabetes 
progression and confirmed in both NMR and LC-MS datasets.  The confirmed 
metabolites were trimethylamine-n-oxide (TMAO), creatine, carnitine, and 
phenylalanine.  TMAO and phenylalanine were both elevated in db/db mice and 
decreased in these mice with age.  Levels of both creatine and carnitine increase in 
diabetic mice with age and creatine was also significantly decreased in db/db mice. 
Additionally, many metabolic markers were found by either NMR or LC-MS, but could 
not be found in both, due to instrumental limitations.  This indicates that the combined 
use of NMR and LC-MS instrumentation provides complementary information that 
would be otherwise unattainable.  Pathway analyses of urinary metabolites and liver, 
muscle, and adipose tissue transcripts from the db/db model were also performed to 
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identify altered biochemical processes in the diabetic mice.  Metabolite and liver 
transcript levels associated with the TCA cycle and steroid processes were altered in 
db/db mice.  In addition, gene expression in muscle and liver associated with fatty acid 
processing was altered in the diabetic mice and similar evidence was observed in the LC-
MS data.  The findings highlight the importance of a number of processes known to be 
associated with diabetes and reveal tissue specific responses to the condition.  When 
studying metabolic disorders such as diabetes, platform integrated profiling of metabolite 
alterations in biofluids can provide important insight into the processes underlying the 
disease.    
 5.2 Introduction 
In both the United States and worldwide, the prevalence of diabetes is increasing.  
In 2003, there were approximately 194 million affected adults (5.1% global population), 
and by 2025, it is projected that the incidence of diabetes will reach 333 million adults 
(6.3% global population).   Type 2 diabetes accounts for approximately 90% of all 
diabetes cases and is projected to be the primary cause of the increasing incidence rate 
(International Diabetes Federation, 2005). 
Of all the animal models available for the investigation of type 2 diabetes, rodent 
models have been the most popular due to short generation time, heritable traits, and cost.  
The most studied spontaneously diabetic mouse model is the db/db mouse, which, due to 
an autosomal recessive defect in the leptin receptor gene, displays several phenotypic 
traits associated with type 2 diabetes (Chen and Wang, 2005) including drastically altered 
metabolic processes.  The widespread metabolic changes associated with diabetes make 
metabolic profiling a particularly important contribution to the discussion of disease 
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progression and prevention.  Although the metabolome is considered to be more closely 
related to phenotype than the transcriptome (Hollywood et al., 2006), any attempt at a 
systems biology approach requires multiple data modalities (e.g. metabolomics, 
transcriptomics) and metabolomics platforms (van der Greef et al., 2007).  
1H nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry- 
(MS) based technologies are the most commonly used for mammalian metabolomics 
(Dunn and Ellis, 2005).  Both approaches allow for the simultaneous measurement of a 
large number of individual metabolites, allowing investigators to identify and validate 
key discriminative markers of disease, drug efficacy, toxicity, or other physiological 
parameters.  Consistency and reproducibility are considered a distinct advantage for the 
use of NMR in metabolic profiling studies (Keun et al., 2002).  MS-based methods are 
also important data platforms and have the specific advantage of a lower detection limit 
(Want et al., 2005).   However, MS data are not as reproducible as NMR due to a non-
linear detector response and ionization. 
The goal of this study was to provide biological insight into metabolic alterations 
associated with diabetes and diabetic progression.  A number of metabolic profiling 
studies of diabetes have been conducted evaluating rodent models (Williams et al., 2006), 
humans (van Doorn et al., 2006), and cross-species comparisons (Salek et al., 2007).  In 
contrast to these studies, this study is an evaluation of cross -experimental and -platform 
results for consistency within the context of biological analysis.  To accomplish this, 
standard and novel methodologies (Gipson et al., 2006; 2008) were used to extract 
information of biological importance from NMR and LC-MS profiles of urine from db/db 
and control (db/+) mice.  This metabolite data, collected over two independent 
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experiments, is put into context with a gene expression dataset that was collected during 
one of the experimental periods.  Additionally, technical issues concerning the use of 
NMR and LC-MS data in metabolomics investigations are discussed.   
5.3 Methods 
5.3.1 Experimental Data 
 Two independent experiments investigating db/db versus db/+ mice were 
evaluated in this study.  In Experiment 1, urine was collected from 8 week old, male mice 
from The Jackson Laboratory (Bar Harbor, Maine) [30 db/+, 31 db/db] and adipose 
tissue, liver, and muscle were collected from the animals 2 weeks later.  Urine samples 
were analyzed by NMR and adipose tissue, liver, and muscle were used for microarray 
analysis (Affymetrix MOE430a).  In Experiment 2, urine samples were collected from 
male db/db and db/+ mice at 8, 12, and 20 weeks of age (10 db/db and 10 db/+ mice per 
collection event).  One of the week 12 control animals was removed from the analysis 
due to fecal contamination of the sample.  The urine samples from the second experiment 
were analyzed both by NMR and LC-MS. 
5.3.2 NMR data 
 Datasets from 2 experiments of Carr-Purcell-Meiboom-Gill (CPMG) NMR 
spectra from urine samples across db/db and db/+ mice were collected on a 700 MHz 
Bruker DRX700 (Bruker BioSpin, GmbH) .  Urine samples were stored at -80°C prior to 
analysis.  Thawed samples were aliquoted into phosphate buffer in D2O (deuterium 
oxide, heavy water) and a solution containing internal NMR reference standard, 3-
trimethylsilyl-(2,2,3,3-2H4)-1-propionate, sodium salt (TSP) δH= 0 ppm, with sodium 
azide was added.  Urine volumes were 400µl where possible, or the total sample volume 
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if less.  Buffered samples were used to minimize differences in shift and shape due to 
second order coupling.  NMR data was preprocessed beginning with automated 
adjustment of the chemical shift of TSP to δH = 0 ppm, application of a semi-automated 
phase correction, and automated baseline adjustment using an automated 0-2nd order 
polynomial and reduction to histogram representations by binning using the method by 
Forshed et al. (2002).   
A bin width of 0.02 ppm was chosen with a 50% tolerance either side of the bin 
boundary.  NMR spectral regions associated with water (4.7-5.0 ppm), urea (5.5-6.1 
ppm), TSP (-0.6-0.6 ppm), and baseline (9.3-10.0 ppm) were removed prior to data 
processing.  To normalize the data, bins were first ranked with respect to the total 
intensity level (summation across individuals) and a normalization factor was calculated 
(1 / ∑ central 50% sample intensities).  The normalized intensity levels for each sample 
were calculated through the multiplication of raw intensity values and normalization 
factors.  Bins associated with glucose (3.20-3.30, 3.37-3.57, 3.69-3.92, 4.63-4.7, 5.20-
5.30 ppm) were removed from the normalization factor calculation, but reintroduced for 
statistical analysis. 
5.3.3 LC-MS data 
The data used in this study were positive polarity UPLC-MS datasets.  
Chromatographic separations were achieved using an ACQUITYTM C18 (100x2.1mm 
i.d., 1.7µm particle size) column (Waters Corporation, Milford, USA) on an 
ACQUITYTM UPLC system (Waters).  Mass spectrometry was performed on a Waters 
LCT PremierTM (Waters MS Technologies, Manchester, UK) orthogonal acceleration 
time-of-flight (oa-TOF) mass spectrometer operating in W optics mode.  Peaks were 
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extracted from the LC-MS data using xcms (Smith et al., 2006).  For this analysis, no 
retention time correction was employed, and the default initialization parameters were 
used with the exception of the full width at half maximum (fwhm) and bandwidth (bw), 
which were each set to 5 scans.  LC-MS peaks were normalized using the same technique 
implemented for the NMR bins with the central 80% of peaks used to calculate the 
normalization factor.   
 To confirm the putative assignments based on the method proposed by Gipson et 
al. (2008), UPLC-MS/MS and spiking experiments of authentic metabolites were 
performed.  These experiments were performed on diluted urine and standard solutions 
using a Waters Q-Tof PremierTM (Waters MS Technologies, Manchester, UK) 
quadrupole, orthogonal acceleration time-of-flight tandem mass spectrometer operating 
in V optics mode.  See Chapter 4 or Gipson et al. (2008) for more details regarding MS 
and MS/MS methods.   
5.3.4 Microarray Data 
 Liver, adipose tissue, and gastrocnemius muscle were collected in 10-wk old 
db/db and db/+ mice in Experiment 1 of this study.  At the time of dissection, liver (100 
to 200 mg), subcutaneous adipose tissue (100 to 350 mg) and gastrocnemius muscle (100 
to 200 mg) were harvested, minced finely (1 to 3 mm) and placed into 5 to 10 volumes of 
RNAlater™ (Ambion, Inc., Austin, TX). RNAlater™, an ammonium sulfate solution, 
was used to prevent degradation of RNA during the experimental procedures. Samples 
were stored on dry ice and transferred to a -80°C freezer until further processing. 
 Tissue from RNAlater™ stocks was weighed, transferred to Trizol reagent 
(Invitrogen, Carlsbad, CA), and homogenized using the MixAMil system (Retsch, Haan, 
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Germany). RNAse-free water, chloroform, and the Trizol-tissue homogenate was spun in 
a Phase Lock Gel (PLG) tube (VWR International, West Chester, PA). Clear aqueous 
supernatant was recovered from the top layer of the PLG, transferred to RNAeasy Mini 
columns (Qiagen Inc., Valencia, CA) and processed according to manufacturer’s 
instructions. RNA samples were DNAse I treated as recommended. RNA integrity was 
assessed by Optical Density (OD) ratios (Spectramax, Molecular Devices Corp., 
Sunnyvale, CA) and ribosomal quality as measured by the Agilent BioAnalyzer RNA 
chips and software (Agilent Technologies Inc., Palo Alto, CA). 
 Five micrograms of mRNA was used for each sample. cDNA synthesis 
(Invitrogen Carlsbad, CA) and in vitro transcription incorporating biotinylated 
nucleotides (Enzo Biochem Inc. Farmingdale, NY) was carried out according to standard 
operating procedures recommended by Affymetrix. Labeling quality was assessed by 
cRNA yields and integrity as monitored by Agilent BioAnalyzer RNA chips and 
software. 
 Hybridization cocktails containing 10 µg of representative sample cRNA were 
loaded onto GeneChip® Mouse Genome 430A Array and hybridized overnight. 
Genechips® were washed and scanned using Affymetrix fluidic stations and scanners. 
Intensity data were captured by Genechip Computer Operating System (GCOS) using the 
algorithm, MAS 5.0.  An initial visual inspection of each chip was completed that 
checked for uniform color, unexpected spots or scratches, and proper grid alignment. 
Technical quality control (QC) of all microarray data was performed using the MAS 5.0 
analysis software. 
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5.3.5 Statistical Analyses 
 All multiplicity correction in this study was performed by controlling for the false 
discovery rate (FDR) as described by Benjamini and Hochberg (1995).  Comparable 
NMR data (8 week old mice) from Experiments 1 and 2 were evaluated for experimental 
consistency.  A Student’s t-test was used to identify significantly altered NMR bins for 
each experiment independently and an ANOVA was performed using both disease status 
and experiment date as independent variables.   
 Univariate and multivariate statistical methods were employed to compare data 
across the metabolomic platforms.  Principal components analysis (PCA) was used to 
visualize the primary separations between individuals based on both the NMR bins and 
LC-MS peaks.  To determine the effect of disease, age, and their interaction on bins and 
peaks, an ANOVA was performed with an FDR of 0.01. 
5.3.6 Enrichment Analysis 
 Data from the Affymetrix MOE430a chip (22,690 gene probes) were normalized 
using the MAS5 procedure prior to use in analyses.  Genes with significantly altered 
expression between db/db and db/+ mice were determined with univariate statistics (t-
test) followed by multiplicity correction.  A FDR of 0.00002 was used that should result 
in less than one false positive.  An enrichment analysis of significantly altered genes was 
performed using the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and 
Genomes (KEGG) databases (The Gene Ontology Consortium, 2000; Kanehisa et al., 
2006).  Enrichment significance was calculated using the hypergeometric distribution 
followed by multiple test correction with an FDR of 0.01.  
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LC-MS derived metabolite enrichment was performed based on a previous 
finding that correlation supported assignments are of higher quality than mass only peak 
assignments (Gipson et al., 2008).  Pathway enrichment was calculated for each of the 27 
(independent variableobserved change = 33) possible significance profiles from the ANOVA 
(independent variable = disease, age, interaction; observed change = up, down, 
unchanged) performed on the metabolomics data.  Here, an enriched pathway is defined 
as one with a statistically significant proportion of high quality assignments in a given 
significance profile.    
5.4 Results 
5.4.1 NMR/LC-MS Platform Comparison 
 The datasets used in this analysis contain a large number of variables, making 
multiple testing correction necessary for statistical interpretation.  The binned NMR 
datasets consisted of 169 discrete spectral regions of which 129 and 91 were significantly 
altered (FDR = 0.001) in experiment 1 and 2, respectively.  Of 70 bins that were 
significantly altered in both experiments, 67 of the bins were statistically significant with 
the same direction of change in both experiments.  The ratio of bins with conflicting 
directional change to significant bins for both experiments decreases with increasing 
stringency of the significance threshold (Figure 5.1).  An evaluation of the data at the 
significance threshold (Figure 5.1) at which no discrepancies between significant bins 
was seen (p = 10E-11) yields 55 bins altered in the same direction when the experiments 
are analyzed independently. An ANOVA (FDR = 0.001), using both experiment and 
disease status as independent variables, found that 50 bins were significantly influenced 
by the experiment and 133 were significantly different based on receptor status. 
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Figure 5.1.  Fraction of NMR bins significant in both experiments, yet with opposite directional 
changes. 
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 Results from the NMR data and the LC-MS data collected during Experiment 2 
were compared for platform consistency.  Prior to inclusion in the analysis, technical 
replicates of the LC-MS peaks were compared and peaks were used in the analysis only if 
the difference between the 2 replicates was less than 10% of the higher intensity peak for 
all samples.  These inclusion criteria led to the retention of 1045 of 2723 peaks, 
indicating that on average, over 98% of the peak technical replicates had a quantitative 
error less than 10%.   
PCA of the NMR and LC-MS datasets reveals that both platforms achieve 
separation between db/db and db/+ mice in the first 2 components (Figure 5.2).  
However, there are differences between the two platforms that lead to differential 
separation of the db/db mice with respect to age.  Specifically, while the LC-MS data 
shows no separation at all in the first 2 principal components with respect to age, the 
NMR data indicates a clear difference between the week 8 and older db/db mice.  
Additionally, there appears to be a separation of week 20 db/db mice into two subgroups. 
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Figure 5.2.   First principal components of the NMR and LC-MS datasets following standard normal 
transformation.   
black: db/db mice; grey: db/+ mice; square: 8 week old mice; circle: 12 week old mice; triangle: 20 
week old mice.
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The ANOVA results, using disease, age, and an interaction term as independent 
variables and individual NMR bins or LC-MS peaks as dependent variables, indicates 
that the two data platforms provide markedly different information (Table 5.1).  This 
analysis reveals that, while 38.4% of the data from the NMR platform and 32.6% of the 
data from the LC-MS platform have a significant disease alteration, 56.1% of the NMR 
bins and 13.2% of the LC-MS peaks have either a significant age or interaction term 
component.     
Investigation of the NMR PCA loadings reveals that the bins most responsible for 
the separation of 20 week old db/db mice are associated with hippurate and m- 
hydroxyphenylpropionic acid (m-HPPA).  A plot of the intensity of hippurate as 
quantified by the confirmed LC-MS peak and the NMR spectra (Figure 5.3) provides a 
visual representation of the subpopulations present in the week 20, db/db mice.  
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Table 5.1.  Enumeration of significant NMR bins and LC-MS peaks.  Results from ANOVA with 
disease, age, and interaction term as independent variables. 
 
Disease / Age / Interaction % (Bins) % (Peaks) 
-  /  -  /  - 30.8% (52) 62.5% (653) 
-  /  -  /  ↑ 15.4% (26) 1.3% (14) 
-  /  -  /  ↓ 14.8% (25) 1.1% (12) 
-  /  ↑  /  - 0.0% (0) 0.8% (8) 
-  /  ↑  /  ↓ 0.0% (0) 0.3% (3) 
-  /  ↓  /  - 0.6% (1) 1.2% (13) 
-  /  ↓  /  ↑ 0.0% (0) 0.2% (2) 
↑  /  -  /  - 10.7% (18) 13.3% (139) 
↑  /  -  /  ↑ 3.6% (6) 0.1% (1) 
↑  /  -  /  ↓ 3.6% (6) 2.2% (23) 
↑  /  ↑  /  - 0.0% (0) 0.7% (7) 
↑  /  ↑  /  ↓ 0.0% (0) 0.2% (2) 
↑  /  ↓  /  - 0.0% (0) 0.3% (3) 
↑  /  ↓  /  ↑ 0.0% (0) 0.2% (2) 
↓  /  -  /  - 2.4% (4) 11.0% (115) 
↓  /  -  /  ↑ 14.2% (24) 3.5% (37) 
↓  /  -  /  ↓ 3.6% (6) 0.3% (3) 
↓  /  ↑  /  - 0.0% (0) 0.1% (1) 
↓  /  ↓  /  - 0.6% (1) 0.3% (3) 
↓  /  ↓  /  ↑ 0.0% (0) 0.4% (4) 
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Figure 5.3.  Mean centered, standard deviation normalized profile of hippurate stratified by disease 
status and age.  
black: db/db mice; grey: db/+ mice; square: 8 week old mice; circle: 12 week old mice; triangle: 20 
week old mice; solid: LC-MS peak; open: deconvoluted NMR spectra (Gipson et al., 2006).
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5.4.2 Validated LC-MS Peaks 
Targeted analytical follow-up of the LC-MS peaks lead to the validation of 11 
peak assignments exhibiting a variety of responses to the experimental conditions (Table 
5.2).  Of the validated peak assignments, glutamate is the only peak that did not meet the 
technical reproducibility criteria.  Visual inspection of the NMR resonances associated 
with validated LC-MS peaks showed that the metabolite profiles were shared by both 
platforms for trimethylamine-n-oxide (TMAO), creatine, carnitine, phenylalanine, and 
phenylacetylglycine (PAG).  The NMR profile of the other metabolites could not be 
assessed due to resonance locations in an overly crowded spectral region (pantothenate) 
or intensity levels below the limit of detection (pipecolate, glutamate, tryptophan, 5-
hydroxytryptophan (5HTP), adenosine, and cortisol).  
5.4.3 Enrichment Analysis 
The transcriptomics data indicates a tissue-specific impact of disease effects.  
Muscle was least impacted with 1378 disease affected probes.  Liver had twice as many 
disease affected (2963) gene probes than muscle.  Adipose tissue was the most 
dramatically impacted, with respect to the number of altered gene probes, with 3700 
disease affected probes.  The GO process enrichment analysis of genes found with 
significant differences between db/+ and db/db mice revealed 13 processes enriched in 
liver, 9 processes enriched in adipose tissue, and 8 processes enriched in muscle (Table 
5.3).  
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Table 5.2.  Validated LC-MS peaks and results from ANOVA 
 
m/z rt (min) Findings Validated ID 
76.07629 0.59 db/db ↑, db/db ↓ with age  TMAO 
130.0859 0.77 ns Pipecolate 
132.0773 0.62 db/db ↓, db/db ↑ with age Creatine 
148.0611 0.87 db/db ↑ Glutamate 
162.1127 0.60 db/db ↑ with age Carnitine 
166.082 2.43 db/db ↑, db/db ↓ with age Phenylalanine 
180.0662 4.38 complex Hippurate 
194.0822 5.16 ns PAG 
205.0981 3.49 db/db ↑ Tryptophan 
220.1185 2.93 ns Pantothenate 
221.093 1.87 db/db ↑, db/+ ↑ with age 5HTP 
268.1065 1.86 db/db ↓ Adenosine 
363.2163 8.55 db/db ↑ Cortisol 
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Table 5.3.  GO processes enriched with gene transcripts significantly altered by disease 
 
Tissue Category Hits Genes OnChip p 
Liver GO:0006412:translation 132 2963 331 9.88E-15 
Liver GO:0008152:metabolic process 181 2963 508 4.30E-14 
Liver GO:0042254:ribosome biogenesis and assembly 45 2963 76 8.29E-13 
Liver GO:0006629:lipid metabolic process 73 2963 167 6.76E-11 
Liver GO:0006118:electron transport 119 2963 341 4.37E-09 
Liver GO:0006631:fatty acid metabolic process 31 2963 59 1.38E-07 
Liver GO:0006869:lipid transport 24 2963 44 1.47E-06 
Liver GO:0006099:tricarboxylic acid cycle 15 2963 23 7.29E-06 
Liver GO:0006956:complement activation 15 2963 25 3.12E-05 
Liver GO:0006694:steroid biosynthetic process 23 2963 48 3.99E-05 
Liver GO:0008610:lipid biosynthetic process 31 2963 75 7.44E-05 
Liver GO:0006957:complement activation, alternative pathway 8 2963 10 0.000129 
Liver GO:0008203:cholesterol metabolic process 18 2963 36 0.000137 
Adipose GO:0006412:translation 159 3700 331 <1.0E-15 
Adipose GO:0042254:ribosome biogenesis and assembly 45 3700 76 2.38E-09 
Adipose GO:0006888:ER to Golgi vesicle-mediated transport 42 3700 73 2.63E-08 
Adipose GO:0015031:protein transport 149 3700 387 1.96E-07 
Adipose GO:0019882:antigen processing and presentation 31 3700 52 5.93E-07 
Adipose GO:0016192:vesicle-mediated transport 42 3700 86 9.26E-06 
Adipose GO:0006464:protein modification process 67 3700 160 2.15E-05 
Adipose GO:0006886:intracellular protein transport 82 3700 205 2.15E-05 
Adipose GO:0006397:mRNA processing 81 3700 204 3.29E-05 
Muscle GO:0007155:cell adhesion 72 1378 367 1.18E-08 
Muscle GO:0006817:phosphate transport 22 1378 69 4.51E-07 
Muscle GO:0005977:glycogen metabolic process 10 1378 20 6.69E-06 
Muscle GO:0006941:striated muscle contraction 9 1378 21 9.03E-05 
Muscle GO:0042759:long-chain fatty acid biosynthetic process 4 1378 4 9.77E-05 
Muscle GO:0055009:atrial cardiac muscle morphogenesis 4 1378 4 9.77E-05 
Muscle GO:0006937:regulation of muscle contraction 8 1378 17 0.000101 
Muscle GO:0007160:cell-matrix adhesion 14 1378 47 0.000127 
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There were 18 KEGG pathways with a minimum of 5 genes (MOE430a chip) 
associated with metabolites in the pathway.  Since none of these KEGG pathways were 
enriched at the proposed significance criteria, the data was evaluated at the less restrictive 
FDRs of 0.001 and 0.05 for gene significance and enrichment significance, respectively. 
The analysis revealed 2 significantly enriched pathways in liver, 1 significantly enriched 
pathway in muscle, and no enriched pathways in fat (Table 5.4).  Several KEGG 
pathways were significantly (FDR = 0.01) enriched with improved quality LC-MS 
metabolite assignments (Table 5.4).  NMR markers of diabetic status that were 
discovered (Connor et al., in preparation) and presented (Gipson et al., 2006) previously 
were also explored.  An examination of KEGG pathways revealed that there were 2 that 
contained at least 4 confirmed NMR markers (Table 5.4).  
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Table 5.4.  KEGG pathways highlighted through sample type specific analyses 
 
Sample Type Pathway KEGG ID 
TA Liver TCA cycle map00020 
TA Liver Fatty acid metabolism map00071 
TA Muscle Glycolysis/Gluconeogenesis map00010 
LC-MS Urine Fructose & Mannose metabolism map00051 
LC-MS Urine Galactose metabolism map00052 
LC-MS Urine Fatty acid elongation in mitochondria map00062 
LC-MS Urine Fatty acid metabolism map00071 
LC-MS Urine C21-steroid hormone metabolism map00140 
LC-MS Urine Limonene & Pinene degradation map00903 
NMR Urine TCA cycle map00020 
NMR Urine Nicotinate & Nicotinamide metabolism map00760 
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5.5 Discussion 
Further progress in metabolome studies are limited by technical challenges such 
as reproducibility, platform selection, and statistical inference.  This work addresses some 
of these challenges by evaluating experimental reproducibility across independent NMR 
studies, comparing NMR and LC-MS results within the context of validated data peaks, 
and by integrating metabolite data with gene expression data.  The results from the 
experimental comparison further confirm the reproducibility of the NMR data platform. 
However, the results also indicate the possibility for over interpretation of data from an 
individual experiment. The comparison of statistical analyses on the individual 
experiments showed that in the absence of multiplicity correction, an investigator could 
expect to make contradictory direction-of-change calls on over 20% of the spectral 
regions at an significance threshold of 0.01 (Figure 5.1).  However, this is not meant to 
imply that only data that is consistent across experiments is reliable or meaningful.  
Instead, it is likely that there are experimental variables that are not controlled for across 
individual experiments, which leads to much of the conflicting information.  As such, 
conflicting directional changes may be indicative of alternative biological states resulting 
from varying experimental conditions.  Nevertheless, increasing the stringency of 
significance thresholding was found to lead to greater agreement between the two 
experiments, suggesting that the strongest biological signals are shared across 
experiments.  As such, these results indicate the need for care when contextualizing data 
from an individual study. 
A particular challenge of global metabolite profiling, whether using MS or NMR, 
is assignment of spectral peaks of interest (Kell, 2004) and as the above findings suggest, 
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care must be taken when attributing physical meaning to a spectral signal.  Here, a 
previously described method was employed that uses biological information to guide the 
LC-MS peak assignment process (Gipson et al., 2008).  For any given MS peak, there 
will be a variety of compounds that can explain the observed mass.  As an example, the 
peak that was confirmed to be cortisol (mz = 363.2163, rt = 8.55 min) through analytical 
validation matches a number of other compounds in the KEGG database through mass 
matching.  In fact, there are 8 compounds with the same chemical formula as cortisol 
(C21H30O5), of which, 5 have biochemical interactions described in KEGG.  While 
assignment of this peak as cortisol putatively explains 36 data interaction pairs, the other 
assignments explain fewer pairs (between 3 and 18).  Interestingly, all 5 of these 
compounds are closely related to cortisol (Figure 5.4).  Along with the assignment 
improvement gained through interaction pair mapping (Gipson et al., 2008), this 
biochemical proximity of similar compounds makes the LC-MS peak enrichment process 
described here an informative approach for evaluating the data.  However, interpretation 
of the data at the individual metabolite level requires analytical follow-up and biological 
interpretation requires cross-platform, multi-experiment verification.  
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Figure 5.4.  Putative KEGG assignments associated with an LC-MS peak interaction pair which fit biochemical interaction criteria.  This peak pair was 
algorithmically identified as belonging to a common instrumental cluster.  Follow-up analytical chemistry validated the cortisol assignment of the 
C21H30O5 peak and confirmed that the C21H28O5 peak was a fragment of cortisol.
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It is generally accepted that no one analytical technique provides a comprehensive 
metabolic profile (Lenz and Wilson, 2006).  Inspection of peak-bin correlation pairs for 
the LC-MS peaks with validated assignments (data not shown) revealed that, with the 
exception of hippurate, the highest correlation coefficients are not associated with bins 
containing resonances from the metabolite of interest.  This finding could be due to MS 
detector response peculiarities (e.g. linear over a limited dynamic range) or the non-
specificity (i.e. contribution of resonances from multiple metabolites) of NMR bins with 
a fixed width of 0.02 ppm.  The fact that hippurate, which has a very strong signal in the 
NMR data, showed a strong correlation between the validated peak and associated NMR 
bins suggests that the non-specificity of the NMR bins is likely more culpable.  This is 
further supported by the fact that, when not precluded by the detection limit or crowded 
spectral regions, visual inspection of the metabolite signals in NMR coincided well with 
the LC-MS findings.  The use of more exhaustive methods of spectral alignment and 
intelligent binning would likely have led to a better correlation between NMR bins and 
LC-MS peaks associated with common metabolites.  However, manual data 
preprocessing is prohibitively time consuming and even sophisticated automated methods 
(Zhao et al., 2006) require some amount of spectral binning.   
While cross-platform verification is a powerful approach for confirmation that the 
interpretation of metabolomics data is accurate, as expected, it was found that the NMR 
profile of several metabolites could not be assessed due to crowded spectral regions or 
detection limit constraints.  In highly proteinaceous biofluids (e.g. blood plasma or 
serum), low molecular weight metabolites are often bound to protein, creating an NMR 
analysis problem due to line-broadening and loss of visibility (Nicholson et al., 1995).  In 
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urine, however, all metabolites with non-labile protons that are above the detection limit 
are observed, producing complex spectra.  Increased variability in the physico-chemical 
parameters (i.e. pH, ionic strength, compound concentrations) of urine, compared to more 
homeostatically-controlled biofluids such as serum, can also affect the absolute 
positioning of data peaks across multiple samples (Lindon et al., 2000).   
The data presented here clearly shows that disease status dramatically alters the 
metabolic profile of affected mice.  Findings from carnitine, creatine, TMAO, and 
phenylalanine LC-MS peaks were confirmed in NMR data.  Previous studies have shown 
that urinary excretion of carnitine is increased in week 20 Zucker (diabetic) rats and 
increases with age in Wistar (non-diabetic) rats (Williams et al., 2005b; 2006).  The 
multi-platform findings suggest that while carnitine levels in control mice are stable with 
age, levels in db/db mice increase with age.  Additionally, although carnitine levels were 
not significantly different (FDR = 0.01, ANOVA) between db/db and control mice, upon 
visual inspection of the data, a marked difference between levels in week 20 mice based 
on disease status was seen (Figure 5.5).  It was found, in both data platforms, that creatine 
is significantly decreased in diabetic mice, but increases, approaching control levels, with 
age.  A previous NMR metabolomics study showed that the decreased creatine urine 
excretion was common in diabetic mice, rats, and humans (Salek et al., 2007).  TMAO 
and phenylalanine were found, in both LC-MS and NMR, to be increased in db/db mice 
with decreasing levels in these animals with age. TMAO has been previously found to 
have higher concentrations in plasma of high fat diet fed mice (Toye et al., 2007).  
Additionally, increased TMAO urine excretion has been seen to be a common trait of 
diabetic mice, rats, and humans (Salek et al., 2007).  In previous studies, transcriptional 
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changes in high fat diet fed mice indicated that a significant change in phenylalanine 
biosynthesis had occurred (Toye et al., 2007) and phenylalanine urine excretion was 
found to be increased in diabetic humans (van Doorn et al., 2006).       
 The remaining metabolites with a significant disease effect could not be 
confirmed in NMR due to technical limitations.  Contrary to a previous study in rats 
suggesting that diabetes increases the capacity of the kidneys to produce or release 
adenosine (Angielski et al., 1989), it was found here that the intensity of the validated 
adenosine LC-MS peak was significantly lower in db/db mice.  In a previous study of 
transcriptional changes in high fat diet fed mice, it was found that a significant change in 
tryptophan metabolism and glutamate metabolism had occurred (Toye et al., 2007).  In 
this study, it was found that the intensity of both the validated tryptophan and glutamate 
LC-MS peaks to be significantly higher in db/db mice.  These findings conflict with 
previous NMR metabolomics studies which showed that tryptophan urine excretion was 
lower in diabetic mice, rats, and humans (Salek et al., 2007) and glutamate urine 
excretion was lower in diabetic humans (van Doorn et al., 2006).  Tryptophan and 
glutamate resonances in these NMR datasets were below the detection limit, and thus, 
cross-platform or experimental confirmation was impossible.  LC-MS data show that 
urinary cortisol excretion is increased in the diabetic mice.  A previous study found that 
streptozotocin induced diabetic rats had significantly increased plasma cortisol levels 
when compared to controls (Radahmadi et al., 2006).  
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Figure 5.5.  NMR and LC-MS peaks of representative samples (2 closest to median value) associated with Carnitine at a.) 8 weeks of age and b.) 20 
weeks of age.
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 Hippurate was shown in this study to have complex behavior based on disease 
status, age, and gut microflora.  The impact that gut microflora can have on hippurate has 
been previously demonstrated (Phipps et al., 1998; Williams et al., 2002) and may 
explain the differences in metabolite excretion of the db/db mice at 20 weeks of age.  
Hippurate urine excretion has been previously found to be both increased (van Doorn et 
al., 2006) and decreased (Salek et al., 2007) in diabetic humans.    
 The current study examined urine metabolite profiles of diabetic db/db and 
control db/+ mice over time.  It is important to note that young db/db mice are 
characterized by high levels of glucose and insulin, whereas older db/db mice have low 
insulin levels likely due to β-cell exhaustion, and also eventually develop renal failure 
(Sharma et al., 2003).  These changes over time in the diabetes phenotype, as well as 
changes in renal function, likely contribute significantly to the metabolite profiles 
observed in the current study.  For example, although not specifically assessed in the 
current study, changes in renal function could account for the differences in metabolite 
profiles within the db/db mice at 20 weeks of age.  In addition, this difference in disease 
phenotype with age in db/db mice may also account for various discrepancies in 
individual metabolites between different studies. 
In this study, PAG and pantothenate LC-MS peaks were found to be unaltered 
over age and disease status.  This finding was confirmed for PAG in NMR, but the 
location of pantothenate resonances in crowded regions of spectra made confirmation 
impossible.  Both of these metabolites have been previously found to be decreased in the 
urine of diabetic rats (Reibel et al., 1981; Salek et al., 2007).   
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 Results from the analysis of biological processes from both the KEGG and GO 
databases are consistent with prior information concerning diabetes and the db/db mouse 
model.  The pathways highlighted in this analysis via evaluation of significant genes, 
improved assignment of LC-MS peaks or NMR derived markers exhibited both the 
complementary and supportive nature of the different methods of inquiry.  Similar to 
previous findings in streptozotocin-induced diabetic rats (Lecker et al., 2004), glycolysis 
was implicated in muscle through querying the KEGG database for significantly altered 
transcripts.  The nicotinate and nicotinamide metabolism KEGG pathway was found to 
contain many confirmed NMR markers.  Findings of increased or decreased metabolite 
levels in this pathway appear to vary in the literature.  The results of this study suggesting 
the increase of urinary NMA are in disagreement with a recent cross-species NMR study 
(Salek et al., 2007), yet the findings of increased 2PY and NMN are supported in this 
same study.  Elsewhere, NMN renal clearance (Thomas et al., 2003) and urinary 
excretion (Sanada and Miyazaki, 1980) have been shown to be decreased in diabetic rat 
models.  Metabolite and liver enzyme levels associated with the TCA cycle and steroid 
processes were found to be altered in db/db mice.  The TCA cycle (Garland et al., 1968; 
Harano et al., 1969; Large and Beylot, 1999) and steroid pathways (Djursing et al., 1982; 
Semple et al., 1988; Atanasov and Odermatt, 2007) association with diabetes are well 
known. Enzyme transcription in muscle and liver associated with fatty acid processing 
was found to be altered in the diabetic mice, and the signal was also seen in the urinary 
LC-MS peaks.  The dysregulation of fatty acid metabolism is known to be influenced by 
leptin and has been implicated with the development of insulin resistance in both the liver 
and skeletal muscle (Shimabukuro et al., 1997; Delarue and Magnan, 2007). 
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5.6 Conclusions 
 In this study, both consistency and complementarity were found across multiple 
experiments and analytical platforms in the pursuit of a better understanding of the 
metabolic changes associated with the db/db mouse model of diabetes.  At the data 
feature level, agreement between 2 separate experiments increased with increasing 
statistical stringency.  At the individual metabolite level, carnitine, creatine, TMAO, 
phenylalanine, and PAG were found to have temporal and disease status profiles in 
agreement across the 2 metabolomic platforms.  At the pathway level, it was found that 
the TCA cycle, fatty acid metabolism, and steroidal processes to be highlighted by 
multiple lines of evidence.  Specifically, each of these pathways was implicated through 
liver transcriptomics and either NMR or LC-MS metabolomics.  Additionally, it was 
found that at each level of investigation, there were findings specific to each experiment 
and data platform.  As such, multiple lines of evidence provide both a confirmatory and 
complementary role in metabolic investigations. 
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CHAPTER 6: Summary & Conclusions 
 
6.1 Summary 
LC-MS and NMR are two of the most used data generation technologies for 
mammalian metabolomics investigations (Dunn and Ellis, 2005).  Both are associated 
with signal complexity and interpretation difficulties, leading to a time consuming data 
analysis process (Robertson, 2005).  This work presents several novel approaches to 
automated metabolomics data analyses, as well as a metabolic marker discovery study 
aided by the described methods.  The experiments conducted to find metabolites and 
metabolic pathways altered in the db/db mouse are the first in which cross-platform 
validation of exploratory biomarkers in this diabetic model are described.  This work 
contains a number of novel contributions to the field of metabolomics and diabetes 
research.  
Chapters 2 & 3 describe the novel approach and validation of using weighted 
spectral features to improve the automated quantification and prediction of exploratory 
biomarkers in NMR data from biofluid samples.  To accomplish this goal, I created a 
flexible interface in R for an existing R function that performs constrained, least-squares 
fitting (Wood, 1994; 2000; 2004).  The interface simplifies the import/export of NMR 
metabolomics data for analysis with the pcls function.  I then evaluated the performance 
of the weighted approach against the unweighted approach using both simulated and 
experimental datasets.  I created the simulated datasets to approximate real biological 
data output from NMR with input from an NMR expert from GlaxoSmithKline.  The 
experimental data was collected and validated by scientists at GlaxoSmithKline.  I re-
analyzed the data using the described automated approach and compared the results to the 
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original validated results.  The automated approach presented in this work, although 
improved through the use of weighting, is not ideal for a number of reasons.  The method 
provides point estimates for individual metabolite level estimates.  It would be useful if, 
instead, a distribution of likely metabolite level estimates were provided.  Additionally, 
the absence of metabolites from the reference spectra database makes accurate estimation 
extremely challenging.  These shortcomings of the described approach could be 
addressed through a Bayesian approach as more a priori information is made available. 
Chapter 4 describes a novel approach for the assignment of MS-based 
metabolomics data peaks.  I developed the entire assignment algorithm.  The current 
implementation uses peak-picked output from the xcms R library as input, but the 
algorithm can handle formatted peak data from any source.  Validation of the method 
required knowledge of the true identity of a number of data peaks.  In order to 
accomplish this, additional analytical chemistry (e.g. spiking experiments) was performed 
to determine the identity of several data peaks.  An LC-MS expert from GlaxoSmithKline 
performed both the LC-MS data generation and the follow-up analytical chemistry 
studies.  The major drawbacks of this assignment approach are the incompleteness of 
existing biochemical interaction databases and the scarcity of disease specific 
experimental datasets.  Together, these limitations prevent investigators from assigning 
physical meaning to a large fraction of MS-based datasets and providing statistical 
estimates of assignment reliability.  With the improvement of biochemical interaction 
databases and increased availability of metabolomics datasets, Bayesian methods can 
provide the framework for addressing these challenges. 
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Chapter 5 describes the first metabolomics study on the db/db mouse model of 
diabetes to provide cross-platform validated markers of disease and disease progression 
for which few metabolomics studies are currently published.  Additionally, the 
experimental design of this study provided the opportunity for an important cross -
experiment and –platform coherence analysis, which is lacking in the literature.  
Experimental protocol, animal handling, and data collection were performed by scientists 
at GlaxoSmithKline.  My contribution to this work, as first author on a manuscript in 
preparation, was primarily in the design of statistical comparisons, data analysis, and 
interpretation of biological relevancy.  Chapter 5 describes multiple lines of evidence 
converging to implicate alterations in the metabolic profile of the db/db mouse.  
Specifically, cross-platform alterations at the pathway level were observed in the TCA 
cycle, fatty acid metabolism, and steroidal processes.  Each of these pathways were 
implicated through liver transcriptomics and either NMR or LC-MS metabolomics. 
6.2 Biological relevance of multi-platform metabolic markers 
The strong signal of dysregulation in these pathways in the db/db diabetic mouse 
model, as evidenced by multi-platform discovery, is not surprising.  The TCA cycle 
(Garland et al., 1968; Harano et al., 1969; Large and Beylot, 1999), fatty acid metabolism 
(Delarue and Magnan, 2007), and steroid pathways (Djursing et al., 1982; Semple et al., 
1988; Atanasov and Odermatt, 2007) are widely known to be associated with diabetes.  
Furthermore, the dysregulation of the TCA cycle (Wlodek and Gonzalez, 2003), fatty 
acid metabolism (Shimabukuro et al., 1997), and glucocorticoid metabolism (Liu et al., 
2003; Masuzaki and Flier, 2003) are known to be influenced by leptin.  The db/db mouse 
model exhibits phenotypic traits associated with type 2 diabetes due to an autosomal 
113 
 
recessive defect in the leptin receptor gene (Chen and Wang, 2005).  An examination of 
the data at the molecular level reveals evidence of the interplay between metabolites and 
the enzymes that mediate their reactions. In this section, I describe the biological 
relevance of metabolic biomarkers discovered in the db/db dataset using the methods I 
developed for LC-MS and NMR analysis. The biological relevance of these markers 
supports their validity as indicators of diabetes and diabetes progression. 
6.2.1 Fatty acid metabolism 
As presented in Chapter 5 (Table 5.3), fatty acid metabolism was found to be 
enriched with liver gene transcripts that were statistically altered (in either direction).  
Additionally, fatty acid metabolism was enriched with high-quality putative assignments 
of LC-MS peaks which were statistically significantly increased in db/db mice (Table 
5.4).  Examining the individual genes responsible for the pathway enrichment revealed a 
statistically significant increase in the transcript levels of fatty acid metabolism 
associated carnitine palmitoyltransferase (Cpt) in the liver of db/db mice.  Cpt 
enzymatically controls the reaction containing palmitoylcarnitine and carnitine (Kanehisa 
et al., 2006).  As described in Chapter 4 (Table 4.1), the assignment of the LC-MS data 
peak associated with carnitine was analytically validated (Gipson et al., 2008) and it was 
identified as a marker of disease progression in db/db mice (Table 5.2).  Carnitine was 
found to be lower than control levels at 8 weeks of age and above control levels at 20 
weeks of age (Figure 5.5).  Carnitine is responsible for the transport of long-chain fatty 
acids from the cytosol into mitochondria and their subsequent oxidation and has been 
previously associated with diabetes in humans (De Palo et al. 1981).  
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6.2.2 TCA cycle 
As presented in Chapter 5 (Table 5.3), the TCA cycle was found to be enriched 
with liver gene transcripts that were statistically altered (either direction).  Additionally, 
the TCA cycle was one of two pathways (Table 5.4) with 4 or more metabolite markers 
validated from the investigated NMR dataset (Connor et al., in preparation; Gipson et al., 
2006).  One of the enzymes in the TCA cycle (Kanehisa et al., 2006) which was 
statistically significantly increased in db/db mice and contributed to the pathway 
enrichment was fumarate hydratase (Fh1).  Fh1 is the enzyme that controls the 
conversion between malate and fumarate (Kanehisa et al., 2006).  Malate and fumarate 
are two of the four TCA cycle associated NMR validated metabolic markers and were 
both found to be statistically significantly increased in db/db mice.   
6.2.3 Steroid metabolism 
As presented in Chapter 5 (Table 5.3), steroid and cholesterol processes were 
found to be enriched with liver gene transcripts that were statistically altered (either 
direction).  Additionally, steroid metabolism was enriched with high-quality putative 
assignments of LC-MS peaks which were statistically significantly decreased in db/db 
mice (Table 5.4).  Hydroxysteriod dehydrogenase 3B (HSD3B) transcript levels were 
statistically significantly decreased in the liver of the db/db mice.  HSD3B was associated 
with the significant enrichment of the steroid biosynthetic process described in Chapter 5 
and is the enzyme responsible for the conversion of 11β, 17α, 21-Trihydroxy-
pregnenolone to cortisol (Kanehisa et al., 2006).  As described in Chapter 5 (Table 5.2), 
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the validated LC-MS peak associated with cortisol was found to be significantly 
increased in db/db mice.   
6.2.4 Pathway connectivity 
 A description of a series of reactions found in the glucose-stimulated insulin 
secretion (GSIS) process provides a good starting point for conceptually linking all of the 
metabolic, enzymatic, and pathway information presented above.  Cpt activity leads to an 
increase in fatty acid β-oxidation and the production of acetyl-CoA.  Next, a portion of 
the produced acetyl-CoA is converted into citrate and follows the TCA cycle, including 
the conversion of fumarate to malate (with the help of Fh1) (Muoio and Newgard, 2006).  
Another portion of the produced acetyl-CoA follows a different path to produce 
cholesterol and then cortisol (Marks et al., 1996).  A recent study describing a 
thiazolidinedione (TZD) drug used for treatment of type 2 diabetes indicates that 
enzymes in all three of the pathways highlighted here are affected by the peroxisome 
proliferator-activated receptor-γ agonist (Wang et al., 2007) which is further evidence 
that the pathway and metabolic markers we found are likely of diagnostic and/or 
therapeutic importance.  The authors also report that the observed down-regulation of 
hydroxysteriod 11-β dehydrogenase has been previously reported as a treatment benefit 
insofar as it leads to a subsequent decrease in cortisol (Berger et al., 2001).    
6.3 Conclusions 
 Metabolomics is an important field of scientific inquiry which allows 
investigators to characterize the metabolic profile of alternative phenotypic states in a 
high-throughput manner.  It is important, however, to understand that follow-up 
analytical chemistry experiments are always required for the validation of the findings of 
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these studies.  Furthermore, although metabolomics datasets can readily provide 
discriminative markers, care must be taken to restrict the interpretation of the results 
within the context of the experimental design.  In order to prove the utility of a given 
metabolite as a biomarker, the specificity of the marker to a particular phenotypic state 
must be demonstrated through examination of data from many alternative phenotypes and 
temporal profiles.  Additionally, in order to extend our understanding of the biological 
mechanisms leading to a particular metabolic profile, a series of focused, hypothesis 
driven studies would be required.  As such, the importance of metabolomics is that it 
provides us with high-quality information to guide metabolic inquiries.  This work has 
outlined the development of informatics methods to explore and analyze NMR and LC-
MS metabolomics data and presented the results from a cross-platform study of the 
metabolic changes associated with diabetes.   
 Each of the studies described here demonstrate that metabolic profiling datasets 
only makes sense when interpreted alongside external, a priori information.  This is due 
to both the complexity of the biological processes under investigation and the open 
profiling technologies used for data generation.  Automated methods of interpretation are 
critical for the systematic and efficient quantification and assignment of metabolite levels 
in complex samples measured by both NMR and MS-based technologies.  Both 
automated methods described here are an example of the utilization of data specific 
information (NMR – bin variance, LC-MS – peak correlations) within the context of 
external information (NMR – reference spectra, LC-MS – biochemical interaction 
database).  Further, the integrated diabetes study indicates the need to contextualize 
biological findings with findings from prior studies.   
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 Due to the interplay between prior information and data specific information in 
the field of metabolic profiling, there is a strong case to be made for the formalization of 
external data inclusion into metabolomics data analysis procedures through Bayesian 
statistics.  In this way, external information can be standardized and treated as a priori 
data which is to be conditioned by the experimental dataset under examination.   
6.4 Future Directions 
6.4.1 Estimation of NMR Metabolite Level Confidence Intervals 
 The preceding study in which differential weighting of NMR spectral regions 
provided an improvement in point estimates of underlying metabolites is valuable as 
more than just an incremental improvement upon previous approaches.  It is also a 
quantitative affirmation of the fact that information content is not uniformly distributed 
throughout the frequency domain of the NMR spectra.  This knowledge, as well as the 
understanding that point estimates are insufficient descriptors of inferred metabolite 
estimates, leads one to believe that a Bayesian framework is the appropriate means for 
exploring NMR metabolomics data.  A Bayesian model of metabolite levels responsible 
for complex NMR spectra would allow for the incorporation of prior distributions of 
metabolite levels and spectral location of signal contributing resonances.  Due to the 
complexity of the biological processes under investigation and the technical and physico-
chemical influences on NMR resonance location, at the present time, both of the prior 
distributions would be speculative.  However, as empirical evidence accumulates and 
predictive models of biological and technical behavior improve, a priori knowledge will 
also improve.  Within this context, methodologies can be developed which will provide 
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quantitative information about the accuracy of the estimates of metabolite levels while 
incorporating and explicitly tracking prior assumptions. 
6.4.2 Bayesian Formalization of MS-based Metabolomics Assignment 
 Likewise, MS-based metabolomics would benefit through the application of 
Bayesian methods.  The work presented here demonstrates the improved assignment of 
MS-based metabolomics peaks using information that is both internal (correlation 
analyses) and external (previously described biochemical relationships) to a given 
collected dataset.  This work could be extended into a formal Bayesian statistical 
framework that would make use of an ever growing knowledgebase of information, as 
well as provide probabilistic information about assignment quality.  An example of the 
ability of a Bayesian framework to organize and incorporate prior information for the 
assignment of MS-based metabolomics can be seen through examining the weights used 
to score the various types of biochemical interactions. 
 Taking a Bayesian view of the use of a function of the probability of occurrence 
for the biochemical interaction weights, as was done in Chapter 3, reveals that the 
weighting scheme is both sensible and extensible upon gathering further information.  
From this perspective, the goal is to know the probability of observing a significant 
correlation (COR), given a particular biochemical relationship (LINKi).  This conditional 
probability can be represented mathematically with its Bayesian equivalent in the 
following Equation: 
p(COR | LINKi) = p(LINKi | COR) x p(COR) / p(LINKi)    (Eq. 6.1) 
In Chapter 3, significance thresholding of the correlation coefficients means that p(COR) 
is reduced to an indicator variable of value 0 or 1.  However, it should be noted that this 
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need not be the case within a Bayesian context.  If p(COR)=0, then the both sides of Eq. 
[6.1] reduce to 0.  If p(COR)=1 then one is left with: 
 p(COR | LINKi) = p(LINKi | COR) / p(LINKi)    (Eq. 6.2)   
Next, if we take an uninformed view of p(LINKi | COR) and assume a uniform 
distribution, then our conditional probability is a function of 1/ p(LINKi), where 
p(LINKi) is equal to the probability of a particular biochemical relationship in the KEGG 
database.  By looking at the information in this way, we see that the sum of the negative 
log(p) across all interaction types (assumes that multiple lines of evidence are 
independent) and uniquely assigned nodes within the network (shown to be the best 
performing weighting scheme in Chapter 3) is equivalent to calculating the probability 
that the correlation matrix is generated by a particular biochemical network.   
 Additionally, validated assignments of MS-based metabolomics peaks provide a 
priori knowledge that is an extremely strong basis to incorporate into metabolite 
assignment software.  Not only will these validated peaks provide strong assignments for 
peaks in subsequent studies occupying the same spectral region, but they will also lead to 
properly informed Bayesian priors for the p(LINKi | COR) term in Eq. [6.2]. 
6.4.3 Knowledgebase Development 
 It can be inferred from both the technical need for external information to guide 
the assignment of metabolomics data and the cross -experimental and -platform analyses 
presented in Chapter 4, that investigations utilizing metabolomics data cannot exist in 
isolation from other studies.  As such, the creation of databases for the storage and 
handling of metabolomics data, such as the Human Metabolome Database (Wishart et al., 
2007), is a critical endeavor for the metabolomics community.  In addition to providing 
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important information for the assignment, and therefore physical interpretation, of the 
data, these databases will also provide the means to compare experimentally induced 
metabolic reconfigurations across diseases and xenobiotic stressors.  
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